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ABSTRACT
The immune system plays a dual role during neoplastic progression. It can suppress tu-
mor growth by eliminating cancer cells, and also promote neoplastic expansion by either
selecting for tumor cells that are fitter to survive in an immunocompetent host or by estab-
lishing the right conditions within the tumor microenvironment. First, I present a model
to study the dynamics of subclonal evolution of cancer. I model selection through time
as an epistatic process. That is, the fitness change in a given cell is not simply additive,
but depends on previous mutations. Simulation studies indicate that tumors are composed
of myriads of small subclones at the time of diagnosis. Because some of these rare sub-
clones harbor pre-existing treatment-resistant mutations, they present a major challenge to
precision medicine. Second, I study the question of self and non-self discrimination by the
immune system, which is fundamental in the field in cancer immunology. By performing a
quantitative analysis of the biochemical properties of thousands of MHC class I peptides, I
find that hydrophobicity of T cell receptors contact residues is a hallmark of immunogenic
epitopes. Based on these findings, I further develop a computational model to predict im-
munogenic epitopes which facilitate the development of T cell vaccines against pathogen
and tumor antigens. Lastly, I study the effect of early detection in the context of Ebola. I
develope a simple mathematical model calibrated to the transmission dynamics of Ebola
virus in West Africa. My findings suggest that a strategy that focuses on early diagnosis
of high-risk individuals, caregivers, and health-care workers at the pre-symptomatic stage,
when combined with public health measures to improve the speed and efficacy of isolation
of infectious individuals, can lead to rapid reductions in Ebola transmission.
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Chapter 1
INTRODUCTION
This dissertation is aimed at understanding some fundamental processes in the human im-
mune system, cancer, and cancer immunology. Cancer is a subclonal evolutionary pro-
cess that is governed by the dynamic interplay of mutation, stochastic drift, and selection
(Greaves and Maley, 2012; Marusyk et al., 2012; Nowell, 1976; Lipinski et al., 2016; Frank,
2007). In the field of cancer biology, the term driver mutation is used to refer to mutations
under positive selection within a population of cells, and the term passenger mutation is
used for mutations that are neutral or deleterious (Martincorena and Campbell, 2015; Vo-
gelstein et al., 2013; McFarland et al., 2013), and increase in frequency due to hitchhiking
alongside driver mutations. A common model of the evolutionary process explaining tu-
mor growth envisions driver mutations causing clonal expansions that sweep through the
tumor cell population and reach fixation (100% frequency) (Fearon et al., 1990; Bozic et al.,
2010). If such a driver mutation did reach fixation, it would appear as a trunk mutation,
present in all the tumor cells. However, tumor clonal architectures are often observed exper-
imentally to be the consequence of a complex branched subclonal processes across multiple
cancer types, with divergent subclones evolving simultaneously (Navin et al., 2010; Camp-
bell et al., 2010; Anderson et al., 2011; Notta et al., 2011; Sottoriva et al., 2013; Campbell
et al., 2008; Gerlinger et al., 2012; Nik-Zainal et al., 2012; Shain et al., 2015; Burrell et al.,
2013; Burrell and Swanton, 2016; Zhao et al., 2016).
In Chapter 2, I present a stochastic model to study the dynamics of the subclonal evolu-
tion of cancer and to assess the extent to which heterogeneous subclonal expansions occur.
By employing a supercomputer to simulate the process, we were able to keep track of all
subclones that arise and die out, or are maintained and grow during the evolutionary pro-
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cess. Under different combinations of the evolutionary parameter values, including those
that have been previously estimated for two cancer types (glioblastoma multiforme and col-
orectal cancer), simulations lead to the conclusion that the distribution of sizes of subclones
carrying driver mutations has a heavy right tail at time of tumor detection, with only 1-4
dominant clones present at ≥ 10% frequency, composing most of the tumor cell popula-
tion. By contrast, our model predicts that the vast majority of subclones will be present at
< 10% frequency. In addition, we find that most of treatment-resistant subclones harboring
driver mutations are often present at low frequency, below the detection limit of standard
sequencing techniques. Moreover, our results suggest that the number of minor subclones
is strongly correlated with the number of numerically dominant clones in a tumor.
The immune system of an organism combats invading pathogens, thereby protecting the
host from disease. Jawed vertebrates, such as humans, have an adaptive immune system
that enables them to mount pathogen-specific and tumor-specific immune responses. The
importance of the adaptive immune response for human health is highlighted by the op-
portunistic infections that afflict individuals with compromised adaptive immune systems.
The flexible adaptive immune system can also go awry, and many diseases (e.g., multiple
sclerosis and type I diabetes) are the consequence of the adaptive immune system failing
to discriminate between markers of self and non-self. Thus, CD8+ T cells must distinguish
immunogenic epitopes from non-immunogenic self-peptides to respond effectively against
an antigen without endangering the viability of the host. In Chapter 3, we interrogated the
biochemical properties of 9,888 MHC class I peptides. We identified a strong bias towards
hydrophobic amino acids (aas) at TCR contact residues within immunogenic epitopes of
MHC allomorphs, which permitted us to develop and train a hydrophobicity-based artifi-
cial neural network (ANN-Hydro) to predict immunogenic epitopes. The immunogenic-
ity model was validated in a blinded in vivo overlapping epitope discovery study of 364
peptides from 3 human immunodeficiency virus 1 (HIV-1) Gag protein variants. Apply-
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ing the ANN-Hydro model on existing peptide-MHC algorithms consistently reduced the
number of candidate peptides across multiple antigens and may provide a correlate with
immunodominance. Hydrophobicity of TCR contact residues is a hallmark of immuno-
genic epitopes and marks a step towards eliminating the need for empirical epitope testing
for vaccine development.
In Chapter 4, we study the effect of early detection in the context of Ebola virus disease.
We evaluated the potential effect of early diagnosis of pre-symptomatic individuals in west
Africa. We used a simple mathematical model calibrated to the transmission dynamics
of Ebola virus in west Africa. The baseline model includes the effects of contact tracing
and effective isolation of infectious individuals in health-care settings. Our findings sug-
gest that a strategy that focuses on early diagnosis of high-risk individuals, caregivers, and
health-care workers at the pre-symptomatic stage, when combined with public health mea-
sures to improve the speed and efficacy of isolation of infectious individuals, can lead to
rapid reductions in Ebola transmission.
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Chapter 2
MODELING THE SUBCLONAL EVOLUTION OF CANCER CELL POPULATIONS
Abstract
Genome sequencing has revolutionized our understanding of the process of somatic evolu-
tion in cancer. Increasing evidence shows that tumor clonal architectures are often the con-
sequence of a complex branched subclonal process. Yet, little is known about the expected
dynamics and the extent to which these divergent subclonal expansions occur. Here, we
study intratumor subclonal heterogeneity and its impact on treatment-resistance by devel-
oping and implementing more than 88,000 realizations of a stochastic evolutionary model
simulating the process. Under different combinations of the population genetic parame-
ter values, including those that have been previously estimated for colorectal cancer and
glioblastoma multiforme, our results show that the distribution of sizes of subclones car-
rying driver mutations has a heavy right tail at the time of tumor detection, with only 1-4
dominant clones present at ≥ 10% ffrequency, composing most of the tumor cell popula-
tion. In contrast, our model also predicts that the vast majority of subclones will be present
at ≤ 10% frequency. We find that these minor, and often undetectable, subclones can har-
bor treatment-resistant mutations. In our analysis, the number of dominant clones (≥ 10%)
in a tumor has a strong correlation with the number of minor subclones. Model predictions
are consistent with empirical data on the number of dominant clones at detectable levels
across different cancer types. Our results contribute to explaining why tumors with greater
numbers of detectable clonal populations are associated with poorer prognosis in multiple
types of cancer.
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2.1 Introduction
Cancer, a subclonal evolutionary process, is governed by the dynamic interplay of mu-
tation, stochastic drift, and selection (Greaves and Maley, 2012; Marusyk et al., 2012; Now-
ell, 1976; Lipinski et al., 2016; Frank, 2007). Although most mutations that steadily ac-
cumulate in our cells are neutral or weakly deleterious, a fraction of these mutations in
a gene or a regulatory element can confer a selective advantage to the cell by increasing
its fitness (Martincorena and Campbell, 2015; Shendure and Akey, 2015; Lynch, 2016;
Hanahan and Weinberg, 2011), and in cancers can result in increased survival of a clone
(Martincorena and Campbell, 2015; Genovese et al., 2014; Fisher, 1958). In the field of
cancer biology, the term driver mutation is used to refer to mutations under positive selec-
tion within a population of cells, and the term passenger mutation is used for mutations
that are neutral or deleterious (Martincorena and Campbell, 2015; Vogelstein et al., 2013;
McFarland et al., 2013), and increase in frequency due to hitchhiking alongside driver mu-
tations. A common model of the evolutionary process explaining tumor growth envisions
driver mutations causing clonal expansions that sweep through the tumor cell population
and reach fixation (100% frequency) (Fearon et al., 1990; Bozic et al., 2010). If such a
driver mutation did reach fixation, it would appear as a trunk mutation, present in all the tu-
mor cells. However, tumor clonal architectures are often observed experimentally to be the
consequence of a complex branched subclonal processes, with divergent subclones evolv-
ing simultaneously (Navin et al., 2010; Campbell et al., 2010; Anderson et al., 2011; Notta
et al., 2011; Sottoriva et al., 2013; Campbell et al., 2008; Gerlinger et al., 2012; Nik-Zainal
et al., 2012; Shain et al., 2015; Burrell et al., 2013; Burrell and Swanton, 2016; Zhao et al.,
2016). While a few clones may dominate the composition of a tumor, minor and often un-
detectable subclones can dominate the clinical course of disease progression and recurrence
(Landau et al., 2013; Schmitt et al., 2015; Maley et al., 2006; Chowell et al., 2016; Bozic
5
and Nowak, 2014; Landau et al., 2015). For example, in patients with chronic lymphocytic
leukemia (CLL) who received chemotherapy, the presence of subclones harboring one or
more cancer-driver genes in the original leukemia impacted prognosis and clinical outcome
(Landau et al., 2013, 2015). More recently, similar findings have been observed across di-
verse cancer types (Zhang et al., 2014; Morris et al., 2016; Andor et al., 2016). Moreover,
several studies have also revealed that tumor cells corresponding to the relapsed clone were
often present as a minor subclone in the primary tumor before the initiation of therapy,
which suggest that mutations contributing to recurrence are selected for during treatment
(Mullighan et al., 2008; Hyo-eun et al., 2015; Roche-Lestienne et al., 2003; Morrissy et al.,
2016; Diaz Jr et al., 2012; Ding et al., 2012; Roche-Lestienne et al., 2002, 2008). A Big
Bang model of tumor evolution has been recently observed in an analysis of 349 samples
from 15 independently derived colorectal tumors (Sottoriva et al., 2015). This model shows
that colorectal tumors grow as a single expansion generating several intermixed subclones
where both clonal and most observable subclonal mutations occur early during transforma-
tion (Sottoriva et al., 2015). These subclones are defined from the founding clone and are
established by the additional mutations they acquired, which may not be present in the bulk
of the tumor. Many subclones carrying driver mutations can remain rare and undetectable
because their abundance falls below the detection limit of standard genome or exome se-
quencing techniques (Campbell et al., 2008; Schmitt et al., 2015; Barber et al., 2015; Tirosh
et al., 2016; Wang et al., 2014; Gerstung et al., 2012). Current standard sequencing meth-
ods have low sensitivity and high false positive rate when detecting mutations below 10%
frequency in the DNA extracted from the tumor sample (Barber et al., 2015). Although
the Bing Bang model anticipates uniformly high levels of subclonal mutations throughout
the neoplasm, a quantitative assessment of this subclonal diversity across cancers, and the-
oretical expectations are needed. Here, to gain insight into the dynamics of the subclonal
evolution of cancer and to assess the extent to which heterogeneous subclonal expansions
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occur, we develop a computational model. By employing a supercomputer to simulate the
process, we were able to keep track of all subclones that arise and die out, or are maintained
and grow during the evolutionary process. Under different combinations of the evolution-
ary parameter values, including those that have been previously estimated for two cancer
types (glioblastoma multiforme and colorectal cancer), simulations lead to the conclusion
that the distribution of sizes of subclones carrying driver mutations has a heavy right tail
at time of tumor detection, with only 1-4 dominant clones present at ≥ 10% frequency,
composing most of the tumor cell population. By contrast, our model predicts that the vast
majority of subclones will be present at< 10% frequency. In addition, we find that most of
treatment-resistant subclones harboring driver mutations are often present at low frequency,
below the detection limit of standard sequencing techniques. Moreover, our results suggest
that the number of minor subclones is strongly correlated with the number of numerically
dominant clones in a tumor. We finally discuss empirical data that supports our findings,
the implications of our model predictions, the strengths of the model, and its limitations.
2.2 Results
2.2.1 Subclonal Evolutionary Model of Cancer Cell Populations
Previous dynamical models developed to study tumor evolution (Bozic et al., 2010; Wa-
claw et al., 2015; Durrett et al., 2011; Beerenwinkel et al., 2007) assume that each driver
mutation affects the fitness of a tumor cell lineage equally (with the exception of ref. (Dur-
rett et al., 2011). They also assume that the fitness effect of a driver mutation is independent
of the other driver mutations carried by the cell. However, these epistatic interactions are a
very central aspect of the dynamics of adaption of asexual populations (Lang et al., 2013;
Breen et al., 2012), and should be relevant to asexual tumor populations as well (Sprouffske
et al., 2012). Moreover, as it is a computationally intensive task, the majority of cancer
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evolution models do not study the extent of heterogeneous subclonal expansions that can
occur simultaneously during the neoplastic process. Clonal heterogeneity is particularly
important because multiple subclones carrying favorable (and potentially even resistance)
mutations can emerge and compete with each other, increasing variation in evolutionary
outcomes, as shown previously in laboratory evolution experiments (Lang et al., 2013;
Hegreness et al., 2006; Levy et al., 2015).
Our computational model is based on a branching evolutionary process (Bozic et al.,
2010; Haccou et al., 2005), where we model selection as an epistatic process (Breen et al.,
2012; Kryazhimskiy et al., 2011). In the model, a subclone is defined as a subpopulation of
cells that descended from another clone but then diverged by accumulating another driver
mutation. Similar to the framework presented in (Bozic et al., 2010), each simulation is
initiated with a single cell carrying a single driver mutation (the potential founder of a
primary tumor) that provides a selective growth advantage over normal neighboring cells.
At each time step, a cell may either die or divide, and it can further acquire an additional
driver mutation in one of the daughter cells at a rate µd . For each driver mutation occurring
during cell division, we sample a selection coefficient from an exponential distribution
of mean s (Hegreness et al., 2006; Orr, 2003), and update the cell fitness f . We assume
that each subsequent driver mutation increases the probability of cell division, defined as
b = 1/2 f = 1/2[wwt +d(1−Πni=1(1− si))] (Kryazhimskiy et al., 2011; Nagel et al., 2012;
Kryazhimskiy et al., 2014; Wiser et al., 2013). The fitness change in a cell produced by a
driver is thus dependent of the other driver mutations and the temporal order at which they
occur in the cell; consequently, each cell lineage has its own fitness trajectory during the
neoplastic process. The parameter wwt represents the fitness of the wild-type cell in which
the first driver occurs, and without loss of generality it is assumed to be 1. The parameter
d is a measure of the maximum possible fitness gain through adaptation; we assume d = 1
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(Nagel et al., 2012). The parameters s1,s2, ...,sn characterize the fitness effects associated
with each of n driver mutations that a cell lineage carries.
By employing a supercomputer (see Materials and Methods for details), we are able to
keep track of all subclones that arise and die out, or are maintained and grow during the
evolutionary process. Because of the limited quantitative knowledge of parameter values
across cancers, we test a range of values for µd and s. The ranges we explored are centered
on values obtained from the literature. The values selected for the driver mutation rate, µd ,
are: 1×10−8,1×10−7,1×10−6, and 1×10−5 alterations per cell division (Shendure and
Akey, 2015; Lynch, 2016; Bozic et al., 2010; Sottoriva et al., 2015; Beerenwinkel et al.,
2007; Vermeulen et al., 2013). And the values chosen for the mean, s, of the exponential
distribution of fitness effects are: 0.1, 0.01, and 0.005 (Bozic et al., 2010; Beerenwinkel
et al., 2007; Vermeulen et al., 2013).
2.2.2 Drift Dominates Early Neoplastic Dynamics
A necessary step in neoplastic initiation is that the first mutated cell lineage survives
stochastic drift to result in a clone growing at the expense of its normal neighbors. The
growth of the first clone is important in increasing the number of cells in which a second
driver mutation could occur, and subsequently, another clone could emerge from the cell
with the second driver and so on until a tumor is formed (Fig. 2.1) (Vogelstein and Kinzler,
2015). To quantify the effect of stochastic drift in neoplastic initiation and to generate at
least 100 clinically detectable simulated tumors (tumor cell populations reaching ≈ 109
cells) for each combination of the chosen parameter values, we ran 88,265 simulations of
the process (Table 2.1). Overall, we observe that out of the total number of realizations
executed, only 1,432 became clinically detectable tumors, despite each simulation being
initiated with a driver mutation. Thus, on average, ≈ 98% of all the initiating mutated cell
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lineages carrying a driver mutation die out early (Table 2.1), which is in line with theoretical
expectations. This result highlights the importance of drift affecting neoplastic initiation.
years later
Driver mutation 
arises
A clone develops Neoplastic 
progression starts
years later
Figure 1. 
Figure 2.1: Schematic representation of the expansion of a single mutated cell into a clonal pop-
ulation under the influence of a driver mutation (yellow circle), and the potential conversion of the
clone into cancer through subsequent driver mutations (green circle).
To test how this model works with parameter values from a known cancer type, we
use estimates from colorectal cancer. It has been experimentally estimated that colorectal
cancer cells divide every 4 days (Bozic et al., 2010; Jones et al., 2008). Assuming this cell
division time in the simulations, we find that the average expected time from onset to clin-
ical detection of the simulated tumors ranges from 1.64 years to 27.97 years, depending on
the values for s and µd (Table 2.1). Additionally, using the parameter values s = 0.005 and
µd = 1× 10−5 per cell division, which have been estimated for colorectal cancer (Bozic
et al., 2010), our model predicts that an average of 18.28 years would take for a colorectal
tumor to develop (Table 2.1). This estimate is concordant with previous reports (Bozic
et al., 2010; Jones et al., 2008). By having generated a total of 1,432 clinically detectable
simulated tumors under a wide range of parameter values, we can determine the general
contribution of each of the parameters to initiation and neoplastic progression. We find,
consistent with a previous report (Beerenwinkel et al., 2007), that selection has a larger ef-
fect on neoplastic initiation than the driver mutation rate (Table 2.1). Moreover, we find that
the average expected time from initiation to detection of a tumor increases with decreasing
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the average fitness effect of driver mutations and with decreasing the driver mutation rate
(Table 2.1).
Table 2.1: Number of simulations performed for each combination of parameter values (s,
µd). The mean time in generations and in years from initiation to clinical detection of a
simulated tumor is also shown. The generation time assigned in the simulations is T = 4
days
s µd realizations
Number of
that reached 109 cells
Number of simulations
reached 109 cells
Percentage of simulations that
generations to detection
Mean number of
detection (years)
Mean time to
0.1 1×10−8 10155 162 1.6% 1596.66 17.50
0.1 1×10−7 1948 112 5.7% 475.08 5.21
0.1 1×10−6 748 134 17.9% 158.54 1.74
0.1 1×10−5 748 111 14.8% 147.50 1.62
0.01 1×10−8 6867 125 1.8% 1807.63 19.80
0.01 1×10−7 6866 113 1.6% 1406.75 15.41
0.01 1×10−6 6866 120 1.7% 1263.80 13.85
0.01 1×10−5 6865 115 1.7% 1018.40 11.16
0.005 1×10−8 11951 102 0.9% 2552.70 27.97
0.005 1×10−7 11751 112 1.0% 2546.85 27.91
0.005 1×10−6 11750 126 1.1% 2046.78 22.43
0.005 1×10−5 11750 100 0.9% 1668.07 18.28
88265 1432 1.6%
2.2.3 Extent of Intratumor Subclonal Variation at Detection
To gain insight into the extent of subclonal populations carrying driver mutations within
a tumor at the time of detection and to determine how the different evolutionary parameters
impact the subclonal composition, we analyzed all the 1,432 detectable tumors generated
by our model. In most tumors, we find that the number of dominant clones, defined here as
a subclone present at≥ 10% frequency in a tumor, ranges from 1 to 4; however, the average
number of dominant clones in a tumor tend to increase with decreasing the average fitness
effect of driver mutations and with increasing the driver mutation rate (Fig.2.2). Across all
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the 1,432 detectable simulated tumors, the average number of dominant clonal populations
is 1.47. Of note, the predicted range by the model on the number of numerically dominant
clones in a tumor is largely concordant with the findings reported in two recent pan-cancer
analyses of intratumor heterogeneity (Morris et al., 2016; Andor et al., 2016). Importantly,
we find that even though only a few dominant clones compose the majority of the cancer
cell population in a simulated tumor (range 90.6% - 99.5%; (Fig.2.2)), the number of minor
subclones present at < 10% frequency is substantial (Fig.2.2); and this number increases
with decreasing the average fitness effect of drivers and with increasing the driver mutation
rate (Fig.2.2). For example, given the parameter values s = 0.005 and µd = 1× 10−5,
which have been estimated for glioblastoma multiforme and colorectal cancer (Bozic et al.,
2010), the model predicts that, on average, 1.8 dominant clones and 2,705 minor subclonal
populations carrying driver mutations compose the tumor.
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Figure 2.2: Intratumor subclonal variation. Bar plots of the log10 average number of dominant
clones present at ≥ 10% frequency in the simulated tumors (red) and the log10 average number of
minor subclones that are present at< 10% frequency (blue). The notation bellow each bar identifies
the combination of parameter values used, and it reads as follows A: s = 0.1; B: s = 0.01; C:
s = 0.005; a: µd = 1× 10−8; b: µd = 1× 10−7; c: µd = 1× 10−6; d: µd = 1× 10−5. The value
shown over each red bar represents the average percentage tumor cell population composed by the
dominant clones. Note that the extent of intratumor subclonal variation is greatly affected by both
the mean, s, of the exponential distribution of fitness effects associated with the driver mutations
and the driver mutation rate, µd .
Since both selection and the driver mutation rate impact the extent of intratumor sub-
clonal variation (Fig.2.2), we find that there is a strong, statistically significant correlation
between the average number of dominant clones and the average number of minor sub-
clones across all simulated tumors (Pearson r = 0.91,P < 0.001; (Fig.2.3)). This result
suggests that the number of detectable clonal populations by standard sequencing tech-
niques may simultaneously reflect the extent of undetectable minor subclones carrying
driver mutations in a tumor.
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Figure 2.3: Relation between the average number of dominant clones and the log10 average
number of minor subclones in the simulated tumors for each combination of parameter values used
as in (A)
For each combination of parameter values, we then computed the probability density
function for the subclone sizes present in the simulated tumors (Fig.2.4). Overall, we find
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that the distribution of subclone sizes harboring driver mutations has a heavy right tail,
with only a few clones present at ≥ 10% frequency in the tumor, and with most subclones
present at frequencies as low as 10−7 (Fig.2.4).Figure 3. 
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Figure 2.4: Probability density function for the log10 sizes of subclones carrying driver mutations
present in the clinically detectable simulated tumors for each combination of parameter values; N
is the number of tumors generated by the model. The distribution has a heavy right tail with only
a few dominant clones present at ≥ 10% frequency, composing most of the tumor cell population
(Fig.2.2), and with the majority of subclones present at frequencies below the detection limit of
standard sequencing techniques.
2.2.4 Differential Fitness Between Dominant and Minor Subclones
A key aspect of our computational model is that it can simulate subclonal heterogeneity-
each evolving cellular lineage has its own fitness, which is dependent on the fitness effects
conferred by the driver mutations and their epistatic interactions. For illustrative purposes,
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we show the subclonal composition and their corresponding fitness in two clinically de-
tectable simulated tumors using the parameter values s = 0.01 and µd = 1×10−5 (Fig.2.5
A); and s = 0.005 and µd = 1×10−5 (Fig.2.5 C).
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Figure 2.5: Variability in subclonal composition, differential fitness among subclones, and pop-
ulation dynamics of progression of two simulated tumors. (A and B) Parameter values used are:
s = 0.01 and ud = 1× 10−5. (C and D) Parameter values used are: s = 0.005 and µd = 1× 10−5.
Each circle represents a subclone carrying a certain number of driver mutations. The color of a cir-
cle corresponds to the fitness of the subclone. The size of a circle is proportionate to the number of
cells composing the subclone. In both cases, the generation time used is T = 4 days. Note that the
relative fitness of some minor subclones is greater than the fitness of the dominant clones present
at ≥ 10% frequency. And, as would be expected, there is substantial intra- and inter- subclonal
variation between the two simulated tumors.
The corresponding population dynamics of both simulated tumors are shown as well
(Fig.2.5 B and D, respectively). We observe that the simulated tumor presented in Fig.2.5
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A has 3 dominant clones present at 41%, 19%, and 10% frequency in the tumor, carrying
1-2 driver mutations. On the other hand, the simulated tumor shown in Fig.2.5 C has only
two dominant clones preset at 80% and 17% frequency, harboring 2 and 1 driver mutations,
respectively. Additionally, we also observe that, as would be expected, there is substantial
intra- and inter- subclonal variation in both cases (Fig.2.5 A and C). More importantly, we
find that, on average, the relative fitness of minor subclones is greater than the fitness of
the dominant clonal populations (Table A.2) and (Fig.2.5 A and C). These results show
that, even though cells acquiring subsequent driver mutations, conferring a fitness advan-
tage, cannot sweep through the population within the timescale of tumor growth. And
consequently, a substantial number of minor and often fitter subclones harboring driver
mutations remain in the tumor at very low frequency.
2.2.5 Resistant Subclones Carrying Driver Mutations Are Present at Low Frequency at
Detection
Populations can adapt to novel environments in two different ways- selection acting on
pre-existing genetic variants and selection acting on novel mutations (Barrett and Schluter,
2008). Adaptation from standing genetic variation is probably to be faster than from novel
mutations, not only because beneficial mutations are immediately available in the new en-
vironment, but also because they may start at higher frequencies (Barrett and Schluter,
2008). We thus tested whether subclones carrying driver mutations could also carry at least
one resistance mutation in the clinically detectable simulated tumors. To test this, we used
all the chosen values for the mean, s, of the exponential distribution of fitness effects as-
sociated with the driver mutations, and the following values for the driver mutation rate
µd : 1×10−5 and 1×10−6 alterations per cell division (Bozic et al., 2010). We assume that
multiple different mutations can independently cause resistance, and a resistance mutation
hence occurs at a rate of 1× 10−8 (Komarova et al., 2014; Komarova and Wodarz, 2005)
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in a cell that coincidentally acquire a driver mutation during cell division. Additionally,
we assume that the resistance mutation is neutral. Under these assumptions and parameter
values, we find that the majority of resistant subclones carrying driver mutations are often
present at low frequency, below the detection limit of standard DNA sequencing techniques
(Fig.2.6).Figure 5A. 
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Figure 2.6: Resistant subclones in the clinically detectable simulated tumors. Probability density
function for the log10 sizes of treatment-resistant subclones carrying driver mutations within in the
primary simulated tumor using the combinations of parameter values.
We then calculated the number of independent resistant subclones within each simu-
lated tumor (Fig.2.7). We find that the maximum number of independent resistant sub-
clones in a particular simulated tumor is 18, and the minimum is 0 (Fig.2.6). Overall, we
find that the number of independent resistant subclones in a simulated tumor increases with
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decreasing the average fitness effect of the drivers and with increasing the driver mutation
rate (Fig.2.7). Therefore, these results along with other studies (Mullighan et al., 2008;
Hyo-eun et al., 2015; Roche-Lestienne et al., 2003; Morrissy et al., 2016; Diaz Jr et al.,
2012; Ding et al., 2012; Roche-Lestienne et al., 2002, 2008; Siravegna et al., 2015) suggest
that the extent of standing subclonal variation in a tumor may be the most important factor
for the evolution of acquired resistance to treatment.
Figure 5B.  
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Figure 2.7: Resistant subclones in the clinically detectable simulated tumors. Number of indepen-
dent resistant subclones in each primary tumor. Each bar represents a simulated tumor. For each set
of parameter values used, N is the number of tumors generated by the model. It is assumed that a
resistant mutation occurs at a rate of 1×10−8 in a cell that coincidentally acquire a driver mutation
during cell division. Resistant mutations are assumed to be neutral.
2.3 Discussion
In this study, we have developed and implemented a stochastic evolutionary modeling
framework to study the subclonal dynamics of cancer progression and to assess the extent to
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which heterogeneous subclonal expansions occur. First, we show that drift substantially af-
fects neoplastic initiation (Table 2.1). This result is expected from the theory of population
genetics. Moreover, we find that selection has a much larger effect on neoplastic initiation
than the driver mutation rate (Table 2.1). These results are in agreement with a report where
the authors quantified the competitive benefit of Apc loss, Kras activation, and P53 muta-
tions in intestinal tumor initiation (Vermeulen et al., 2013). They showed that most mutated
cells are lost and that clones in colitis-affected intestines carrying P53 mutations are par-
ticularly favored in tumor initiation. Additionally, we show that the average expected time
from onset to clinical detection of a tumor increases with decreasing the average fitness
effect associated with the driver mutations and with decreasing the driver mutation rate
(Table 2.1). Altogether, we hypothesize that the fitness effects conferred by driver genetic
alterations in certain sporadic childhood cancers should be greater than those associated
with drivers in sporadic adult cancers. For example, in chronic myeloid leukemia, the
fitness effect conferred by the chromosome translocation juxtaposing the BCR and ABL
genes may be quite large, and consequently, this single genetic alteration may be all that is
required for tumor initiation and progression (Michor et al., 2006; Tomasetti et al., 2015).
A statistical strength of this study is that we were able to simulate over 1,400 clinically
detectable tumors, from which we could analyze and gain important biological insights.
Across all the combinations of the chosen evolutionary parameter values, our analysis show
that the distribution of sizes of subclones carrying driver mutations has a heavy right tail
at the time of tumor detection, with only 1-4 dominant clones present at ≥ 10% frequency,
composing most of the tumor cell population (Fig.2.2). In contrast, our model predicts that
the vast majority of subclones will be present at < 10% frequency in the tumor (Fig.2.2).
We also find that the number of these minor subclones present at < 10% increases with
decreasing the average fitness effect of drivers and with increasing the driver mutation rate
(Fig.2.2). Additionally, we find that there is a strong, statistically significant correlation
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between the average number of numerically dominant clones and the average number of
minor subclones across all simulated tumors (Fig.2.3).
The distribution of subclones sizes inferred by our model is qualitatively similar to
that found in a recent study where the authors used ultra-deep sequencing technology to
detect mutations in specific known cancer genes in biopsies of sun-exposed eyelids from
different individuals (Martincorena et al., 2015). Moreover, the predicted range by the
model on the number of dominant clonal populations is largely concordant with two recent
pan-cancer analyses of intratumor heterogeneity (Morris et al., 2016; Andor et al., 2016).
In one of these studies, the authors analyzed over 3,300 tumors and integrated SNP array
copy number and whole exome sequencing mutational data from The Cancer Genome Atlas
(TCGA) to infer the number of clonal populations present in multiple tumor types (Morris
et al., 2016). They found that 92% of all the tumors analyzed had between 1 and 4 clonal
populations at detectable levels by standard sequencing methods (Morris et al., 2016).
By employing ultra-deep sequencing technology to study intratumor subclonal diver-
sity in patients with CLL, it has been shown the presence of rare subclones at frequencies
down to the limit of detection for depth of this specific sequencing method, 10-4 (Camp-
bell et al., 2008). Our model predicts that minor subclones carrying driver mutations can
be present in a tumor at lower frequencies, 10-7 (Fig.2.4). Importantly, we find that these
often undetectable minor subclones can harbor treatment-resistant mutations (Fig.2.5 A).
These results are in line with previous reports showing that tumor cells corresponding to
the relapsed clone were often present as a rare subclone in the diagnostic tumor before the
initiation of treatment (Mullighan et al., 2008; Hyo-eun et al., 2015; Roche-Lestienne et al.,
2003; Morrissy et al., 2016; Diaz Jr et al., 2012; Ding et al., 2012; Roche-Lestienne et al.,
2002, 2008; Siravegna et al., 2015). We also find that the number of independent resis-
tant subclones in a simulated tumor depends on the population genetic parameter values-
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it increases with decreasing the average fitness effect of the driver mutations and with in-
creasing the driver mutation rate (Fig.2.7).
Given that cancer is the result of a very complex process, our approach has some lim-
itations. First, we have not taken space into consideration in our computational model,
which may restrict the expansion of certain subclonal populations during the neoplastic
process. Thus, our modeling framework may be more suitable for cancers that develop in
the absence of spatial constraints. Second, the host immune system has not been taken into
account, which has been demonstrated to have an important role for both cancer suppres-
sion and promotion (Schreiber et al., 2011). Third, future studies should extend this work
and consider non-cell autonomous interactions, as well as “common good” factors, which
are likely to be a strong influence on subclonal dynamics (Marusyk et al., 2014). Despite
these caveats, our model captures some essential features of the dynamics of subclonal
evolution of cancer progression. The subclonal dynamics predicted by our model are con-
sistent with the “Big Bang” model (Sottoriva et al., 2015), where clonal driver mutations
and most detectable subclonal drivers occurred relatively early during tumor growth. This
result is in contrast with the traditional clonal selection model, where sequential stepwise
accumulation of drivers leads to fitter clones that sweep through the population (Fearon
et al., 1990; Bozic et al., 2010).
In conclusion, our modeling framework serves as a proof-of-concept to test that a sub-
stantial number of subclonal populations carrying driver mutations will remain rare and
undetectable within a tumor because their abundance falls below the detection limit of
standard genome sequencing methods. Additionally, these minor and often undetectable
subclones can also harbor treatment-resistant mutations, which present a major challenge
for personalized medicine and clinical management. Altogether, our findings explain why
tumors with greater numbers of detectable clonal populations are associated with poorer
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prognosis across multiple cancer types (Landau et al., 2013; Zhang et al., 2014; Morris
et al., 2016).
These results suggest that driver mutations that have been identified in individual tu-
mors through standard genome sequencing (Lawrence et al., 2013) are likely to constitute
only the “tip of the iceberg”, with several driver mutations that may impact the evolution-
ary dynamics of cancer progression never rising above very low frequencies, until the time
point when treatment starts.
2.4 Materials and Methods
2.4.1 Computer Code Availability
The computer code ‘tumorsim.scala’ is available at:
https://github.com/WilsonSayresLab/TumorHeterogeneity.
2.4.2 High Speed Algorithm Considerations
We used a hierarchical data structure to store common attributes for all cells within the
same subclonal population.
2.4.3 Software Tools
The following open-source platforms and programming languages were used for tu-
mor simulation, monitoring and analysis: Apache Hadoop (HortonWorks 2.6.0) - software
framework written in Java for distributed storage and processing of very large data sets over
commodity hardware clusters. Apache Hive (1.2.1 spark HiveMetastoreConnection version
1.2.1, interactive hive-cli-0.14) - external data warehousing stacked on Hadoop, provides
simulation monitoring, data summarization, query and analysis. Apache Scala (2.10.5)
functional programming language that utilizes the JVM (Java Virtual Machine) for plat-
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form independency, controls tumor simulation logic. Apache Spark (1.6.0 with a min of
1.4.0) - distributed computing framework originally developed at UC Berkeley AMPLab,
stacked on top of Scala and distributed over Hadoop, tracks tumor array memory across
multiple machines. Bash (Sun AMD64 Linux 2.6.32− 504.el6.x8664) Bash is a UNIX
shell and command language; various scripts used for monitoring, analysis and data export
to spreadsheets or other visualizations. Java/JDK (Oracle 1.7) - Spark, Scala and Hive are
converted to run in the java virtual machine for platform independency. Microsoft Excel
(2013) - for aggregates and table visualizations. Module (3.2.10) - Bash environment man-
agement scripting un/loader. Tableau (public 9.1 to 9.3) - for visualization of subclonal
composition of simulated tumors. YARN (2.2.4.2-2) - Yet Another Resource Manager,
manages Hadoop data and hardware resources.
2.4.4 Hadoop Cluster Configuration
The computation and data intensive piece includes a 44 node HDP 2.3 cluster on Dell
PowerEdge 720xd servers. Each of the 40 worker nodes has 128GB ram, 2x Intel E5-
2640 6 core processors and 22TB of disk. The cluster backbone network consists of 10Ge
HA top of rack switching combined with Intel x520 10Ge NICs in each server. Although
the tumor simulator can run parallel jobs utilizing multiple resources, the demands upon
the hadoop NameNode (worker, memory, disk resource managment) are quite exhaustive;
therefore, it is suggested to run sequential jobs on a single node for as many images as
needed to emulate parallelization.
2.4.5 Statistical Analysis
We created scripts on RStudio (Version 0.99.891) to analyze the data sets, perform
statistical analysis, and generate most of the figures (with the exception of the figures dis-
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playing subclonal composition of simulated tumors). All the R scripts are available upon
request.
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Chapter 3
TCR CONTACT RESIDUE HYDROPHOBICITY IS A HALLMARK OF
IMMUNOGENIC CD8+ T CELL EPITOPES
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Abstract
Despite the availability of MHC-binding peptide prediction algorithms, the development
of T cell vaccines against pathogen and tumor antigens remains challenged by inefficient
identification of immunogenic epitopes. CD8+ T cells must distinguish immunogenic epi-
topes from non-immunogenic self-peptides to respond effectively against an antigen with-
out endangering the viability of the host. Since this discrimination is fundamental to our
understanding of immune recognition, and critical for rational vaccine design, we interro-
gated the biochemical properties of 9,888 MHC class I peptides. We identified a strong bias
towards hydrophobic amino acids (aas) at TCR contact residues within immunogenic epi-
topes of MHC allomorphs, which permitted us to develop and train a hydrophobicity-based
artificial neural network (ANN-Hydro) to predict immunogenic epitopes. The immuno-
genicity model was validated in a blinded in vivo overlapping epitope discovery study of
364 peptides from 3 human immunodeficiency virus 1 (HIV-1) Gag protein variants. Ap-
plying the ANN-Hydro model on existing peptide-MHC algorithms consistently reduced
the number of candidate peptides across multiple antigens and may provide a correlate
1L.S.K, J.N.B, and K.S.A are senior co-authors
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with immunodominance. Hydrophobicity of TCR contact residues is a hallmark of im-
munogenic epitopes and marks a step towards eliminating the need for empirical epitope
testing for vaccine development.
3.1 Significance Statement
The design of effective T cell vaccines against pathogens and tumor antigens is chal-
lenged by the highly inefficient identification of the subset of peptides from a given antigen
that effectively stimulate an immune response. Here, we report that the relative hydropho-
bicity of TCR contact residues is markedly enriched in immunogenic MHC class I epitopes
in both human and murine MHCs, and in both self and pathogen-derived immunogenic
epitopes. Incorporating hydrophobicity into T cell epitope prediction models increases the
efficiency of epitope identification, which will manifest in time and cost of T cell vaccine
development. Amino Acid hydrophobicity may represent a biochemical basis by which T
cells discriminate immunogenic epitopes within the background of self-peptides.
3.2 Introduction
The interaction of CD8+ T cells with peptide-MHC complexes (pMHCs) is a key
event in the development of cell-mediated immunity (Grakoui et al., 1999). MHC class
I (MHC-I) molecules typically present 8-11 aa peptides derived predominantly from pro-
teasomal degradation of intracellular proteins, either self-peptides or infection-derived anti-
gens (Blum et al., 2013). T cell receptors (TCRs) from CD8+ T cells bind antigenic pMHC
molecules, triggering a downstream signaling cascade that leads to T cell activation, differ-
entiation, and ultimately to cytolysis of target cells presenting the same epitope (Hennecke
and Wiley, 2001). Vaccines and immunotherapies for the treatment of infection and cancer
seek to incorporate cytotoxic T cell (CTL) epitopes, but defining such epitopes remains
a costly and arduous process (Purcell et al., 2007). Understanding the molecular basis
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of TCR-pMHC recognition will aid discovery of immunogenic epitopes in infectious and
autoimmune disease.
During thymic development, CD8+ T cells undergo both positive and negative selection
to acquire the ability to discriminate antigenic peptides from self-peptides (Hogquist et al.,
1994). Costimulatory signals can enhance this discrimination (Medzhitov and Janeway,
2002), but a primary event that triggers CD8+ T cell activation is the non-covalent pMHC-
TCR interaction. Proteasomal cleavage patterns and binding affinities of peptides to dif-
ferent MHCs have been extensively studied (Falk et al., 1991; Rammensee et al., 1999;
Kubo et al., 1994). In contrast, the biochemical basis of immunogenic epitopes are less
well-defined (van der Merwe and Dushek, 2011). T cell epitope discovery is complicated
by the codominance and polymorphism of MHC alleles, diversity of antigens (both in-
fectious and self-antigens), limited mass spectrometry-based confirmation of MHC-bound
peptides, and a scarcity of experimentally confirmed immunogenic epitopes within the in-
fectious and self-proteome (Purcell et al., 2007). As a result, T cell epitope prediction
algorithms have focused on aa binding affinity for specific MHC-motifs and the proteins
proteasomal cleavage pattern to identify candidate T cell epitopes (Honeyman et al., 1998;
Moutaftsi et al., 2006; Nielsen et al., 2007; Tenzer et al., 2005). Although computational
tools have improved over the past decade, they have not been trained to predict immuno-
genicity. The major limitation when using such prediction algorithms is the presence of
a significant number of binders from a given antigen that will never lead to an immune
response (Newell et al., 2013). Thus, immunogenic CTL epitopes fulfill additional criteria
that go beyond antigen processing and MHC-binding.
Here, we sought to identify the biochemical criteria that define immunogenicity within
the subset of MHC-I binding peptides. Using a curated repository of MHC-I epitopes from
the Immune Epitope Database (IEDB) (Vita et al., 2010), we evaluated the biochemical
properties of aas that discriminate between immunogenic epitopes and non-immunogenic
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self-peptides. We found a strong bias towards hydrophobicity in aa residues of immuno-
genic CTL epitopes that is highly selective for exposed TCR contact residues. Using these
criteria, we trained an artificial neural network (ANN) model to identify immunogenic CTL
epitopes from a data set and empirically assessed our prediction model for 3 human immun-
odeficiency virus 1 (HIV-1) Gag protein variants in a murine model of immunogenicity. We
demonstrate the utility of this ANN model, which has the potential to significantly enhance
the efficiency of T cell epitope discovery.
3.3 Results
3.3.1 Amino Acid Use Differs Between Immunogenic and Non- immunogenic Peptides
CTLs recognize immunogenic epitopes from a background of poorly immunogenic
self-peptides. To understand the biochemical basis of differences between these two classes
of peptides, we retrieved all known MHC class I-binding peptides reported as T cell reactive
(hereafter immunogenic) and self-peptides from MHC-ligand elution experiments with no
known immunogenicity (hereafter non-immunogenic) from IEDB. Any eluted peptide that
was immunogenic (either pathogen derived or self-antigen derived) was excluded to gen-
erate two mutually exclusive datasets that avoid any potential bias. Out of the 34,586 total
retrieved peptides from IEDB, 5,035 8-11mer non-redundant peptides were reported to be
immunogenic and 4,853 were non-redundant non-immunogenic and were used for further
analysis. Frequency distributions of aas in 8-11mer immunogenic and non-immunogenic
peptides showed significant variability in aa composition (Fig. B.1 A).
To identify overrepresentation of certain aas in immunogenic epitopes, we computed a
probability ratio for each aa. We then performed a correlation analysis between the prob-
ability ratio of each aa and three major biochemical properties using independent numeric
scales: hydrophobicity (Kyte-Doolittle) (Kyte and Doolittle, 1982), polarity (Grantham)
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(Grantham, 1974), and side chain bulkiness (Zimmerman) (Zimmerman et al., 1968) (Table
B.3). We found a strong, statistically significant correlation between probability ratios and
hydrophobicity values (Spearman ρ = 0.71,P = 4.24×10−4; (Fig. 3.1 A)). Similarly, we
also found a negative correlation between probability ratios and polarity of aas (Spearman
ρ = −0.77,P = 6.97× 10−5; (Fig. 3.1 B)), with highly polar aas being underrepresented
in immunogenic epitopes. No significant correlation was observed with aa side chain bulk-
iness (Fig. 3.1 C). Most of the overrepresented and strongly bulky aas were also strongly
hydrophobic. Cysteine, a non-polar hydrophobic aa was an outlier in the immunogenic
dataset. Excluding cysteine did not change significantly our results (Fig. B.1 D ).
Two potential sources of bias in our analyses were the variation in peptide length of
MHC-I peptides and the dominance of human leukocyte antigen (HLA) A2 epitopes within
existing databases. Therefore, we performed the analyses on the 9mer epitopes (Fig. B.1
B) and on HLA class I restricted peptides excluding HLA-A2 peptides (Fig. B.1 C). Within
these subsets, the overrepresentation of non-polar, hydrophobic aas in immunogenic epi-
topes was maintained.
3.3.2 Hydrophobicity Bias in Selective TCR Contact Residues
We first compared the mean hydrophobicity of each residue between immunogenic and
non-immunogenic peptides using the Kyte-Doolittle numeric hydrophobicity scale. Im-
munogenic 9mer epitopes were significantly more hydrophobic than non-immunogenic
9mer peptides at each residue (P < 1.6× 10−5; (Fig. 3.2 A) and (Table B.4)). We ob-
served similar results in 10mer peptides (P < 2× 10−7 at every residue; (Fig. B.2 A)),
and within HLA-A2 excluded 9mer and 10mer subsets (Figs. B.2 B and C). Because the
immunogenic dataset is biased to pathogen-derived immunogenic epitopes, we performed
similar analyses between immunogenic self-epitopes and non-immunogenic self-peptides
(P < 1× 10−4 at all residues, except P5 and P6; (Fig. B.2 D)). We further compared im-
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munogenic HLA-A2 restricted 9mer epitopes derived from pathogens with those derived
from self-antigens and observed no significant difference in hydrophobicity (P > 0.05 at
each aa residue except P6, P= 0.04; (Fig. B.2 G)) revealing that T cells that escape thymic
deletion recognize self-peptides with a hydrophobicity profile that is virtually the same as
that of pathogen-derived epitopes. Lastly, to evaluate if there is potential bias created by
using peptide immunization experiments, we did the same analysis using immunogenic
epitopes identified using whole “Organism” as the immunogen (P < 0.01 at all residues
except P1, P5 (Fig. B.2 E)). Thus, our results demonstrate a preference for hydrophobicity
in immunogenic epitopes across antigenic sources (self and pathogen) and MHC molecules
(HLA-A2 and non-HLA-A2).
The location of anchor residues and TCR contacts have been mapped for many MHC
peptides (Rudolph et al., 2006). If the observed bias toward non-polar hydrophobic aas
within immunogenic epitopes affects TCR affinity, we predicted that it would be selec-
tive for TCR contact residues. We analyzed the mean hydrophobicity along the pep-
tide for the highest represented MHC epitopes within the database: HLA-A2 (Fig. 3.2
B), and murine MHC H-2Db and H-2Kb (Fig. 3.2 C and D). HLA-A2 restricted 9mer
peptides are anchored at residues P2 and P9, with P6 as an auxiliary anchor. We ob-
served no statistical difference in hydrophobicity between the anchor residues of immuno-
genic and non-immunogenic peptides (P2,P = 0.9;P9,P = 0.08; (Fig. 3.2 B)). The ob-
served difference in hydrophobicity was at specific TCR contact residues P4, P7 and P8
(P4,P = 6.3× 10−12;P7,P = 5× 10−13;P8,P < 2.2× 10−16). In contrast, the auxiliary
anchor P6 was more hydrophobic in non-immunogenic peptides (P = 3.1×10−7). Similar
results were found for HLA-A2 restricted 10mer peptides (Fig. B.2 F).
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Figure 3.1: Probability ratio [P(xIimmunogenic)/P(Inonimmunogenic)] of each amino acid as
a function of its corresponding biochemical property. Each probability of each amino acid was
computed from the frequency distribution of immunogenic epitopes and nonimmunogenic peptides.
Biochemical properties analyzed were (A) hydrophobicity (Kyte and Doolittle, 1982), (B) polarity
(Grantham, 1974), and (C) side-chain bulkiness (Zimmerman et al., 1968). A probability ratio > 1
indicates overrepresentation of the amino acid in the immunogenic dataset. The overrepresented
outlier cysteine (C) was omitted for scale. Spearman correlations coefficients (ρ) are shown
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Figure 3.2: Hydrophobicity comparison at each residue position between immunogenic and non-
immunogenic MHC-I peptides. Each peptide sequence in the dataset was transformed into a nu-
meric sequence based on amino acid hydrophobicity, and the mean hydrophobicity at each position
was calculated. (A) All immunogenic and nonimmunogenic MHC-I 9-mers; every residue had
P < 1.6105. (B) HLA-A2restricted immunogenic and nonimmunogenic 9-mers. (C) Murine MHC
H-2Dbrestricted immunogenic and nonimmunogenic 9-mers. (D) Murine MHC H-2Kbrestricted
immunogenic and nonimmunogenic 8-mers. Down-arrows in BD indicate anchor residues based on
specific MHC motifs. ∗P< 0.008 in that residue position. P values are listed in SI Appendix, (Table
B.3).
To determine if the difference in hydrophobicity was species-specific, we evaluated
the subset of known mouse MHC H-2Kb restricted 8mer peptides. Again, we observed
a marked increase in relative hydrophobicity for the TCR contact residues P6 and P7 of
immunogenic epitopes (P6,P = 7× 10−5;P7,P = 1.1× 10−6) but no difference in an-
chor residues (P5,P = 0.67;P8,P = 0.15; (Fig. 3.2 C)). As observed with HLA-A2, the
auxiliary anchor residue P3 was more hydrophobic in non-immunogenic peptides (P =
0.005). Finally, we analyzed mouse MHC H-2Db restricted 9mer peptides and observed
that P7 and P8 TCR contact residues were more hydrophobic in immunogenic epitopes
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(P7,P = 1.1× 10−4;P8,P = 0.001; (Fig. 3.2D)), with no difference in anchor residue P9
(P = 0.127). One exception was the anchor residue P5, which was more hydrophobic in
immunogenic epitopes (P = 4.9× 10−10). This discrepancy might be due to the presence
of other potential anchors at P5 (apart from Asn) within immunogenic dataset. Hence we
demonstrate that the observed bias towards relative hydrophobic aas in immunogenic epi-
topes is selective for TCR contact residues.
3.3.3 Differential Hydrophobicity Can Predict Immunogenic CTL Epitopes
While MHC-binding is necessary for antigen presentation, it is not sufficient to stimu-
late an immune response. We predicted that hydrophobicity could be incorporated into ex-
isting binding algorithms to improve prediction of CTL epitopes. To test this hypothesis, we
used the IEDB-consensus binding prediction tool to generate peptide predictions for HLA-
A2 restricted peptides (9, 10mers) for two viral proteins: polyprotein from dengue virus
type 1 (DENV1) and tegument protein pp65 from cytomegalovirus (CMV). Using mean
hydrophobicity of aas in TCR contact residues (all residues except anchors: P2, P6, and
P9 or P10), each predicted peptide was re-ranked with decreasing TCR contact hydropho-
bicity values (Fig. 3.3). The rate at which experimentally defined HLA-A2 restricted CTL
epitopes (Table B.5) were identified was increased using hydrophobicity-based predictions
compared to IEDB-consensus binding predictions (Fig. 3.3 A and B). As a negative control,
we performed re-ranking of top predictions from the 2 proteins using mean hydrophobicity
of just anchor residues (Fig. 3.3 C and D). The rate of prediction of HLA-A2 restricted
CTL epitopes was similar to IEDB-consensus binding predictions, confirming that relative
hydrophobicity impacts immunogenicity and not HLA-binding. These results suggest that
using TCR contact hydrophobicity could improve prediction of immunogenic epitopes.
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Figure 3.3: Efficiency of predicting experimentally defined HLA-A0201 restricted immunogenic
epitopes using mean hydrophobicity of TCR contact residues (straight lines) compared to IEDB
consensus binding tool (IEDB-Bind) are shown (dashed lines). Tegument protein pp65 from cy-
tomegalovirus (CMV) and polyprotein from dengue virus type 1 were used for predictions. (A-B)
Predicted peptides from the IEDB-Bind were re-ranked using mean hydrophobicity of TCR contact
residues. (C-D) Predicted peptides from the IEDB-Bind were re-ranked using mean hydrophobicity
of anchor residues.
3.3.4 Hydrophobicity-based ANN Prediction Model
The relative contribution of each aa residue to immunogenicity varies between MHC
allomorph and is motif-dependent (Fig. 3.2) and (Table B.4). Furthermore, the immuno-
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genicity of a peptide might result from nonlinear interactions between different TCR con-
tact residues. Artificial neural networks (ANN) are designed to handle such nonlinearity
(Honeyman et al., 1998) . Therefore, we developed and trained an ANN-based predic-
tion model of immunogenicity using aa hydrophobicity (ANN-Hydro) with the goal of
improving existing CTL epitope prediction algorithms for H-2Db and HLA-A2. Each pep-
tide sequence in the H-2Db and HLA-A2 datasets was transformed into a corresponding
numeric sequence based on the hydrophobicity value of aas and were used as the train-
ings sets for the two ANN-Hydro models (Fig. B.3). An initial assessment of the trained
ANN-Hydro model for HLA-A2 assigned a good probability of immunogenicity to 54/64
(> 80%) experimentally defined HLA-A2 restricted epitopes from 3 recent studies (Newell
et al., 2013; Assarsson et al., 2008; Weiskopf et al., 2011) (P< 0.001, compared to the dis-
tribution of probabilities of immunogenicity of 64 randomly generated 9mer peptides) (Ta-
ble B.6). We then developed an epitope discovery strategy incorporating the ANN-Hydro
model to predict a previous set of experimentally validated H-2Db and HLA-A2 epitopes
from 5 pathogen and 5 tumor antigens (Table B.7). The IEDB-consensus MHC-binding
prediction algorithm was used to obtain a list of predicted peptides for each antigen, which
were each assigned a normalized binding score (SB). Since T cell epitopes are a subset of
predicted peptides that bind to MHC molecules, normalized scores (SI) based on probabili-
ties of immunogenicity obtained by ANN-Hydro were assigned to each peptide (Fig. B.3).
We then defined a total score (S) as S = SB SI for the rate of identifying CTL epitopes
from the list of predicted H-2Db and HLA-A2 peptides from each antigen. The total score
is therefore dependent on the contribution of both scores, reflecting two critical aspects:
binding and immunogenicity (Fig. B.3). Our strategy of re-ranking by prioritization of
high-binding and high-immunogenic peptides over other predicted peptides ((Fig. B.3),
Materials and Methods), scored 42 out of the 43 H-2Db and HLA-A2 9mer epitopes within
the top 20 ranked peptides (Table B.7). In contrast individual prediction algorithms, ranked
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the same epitopes up to rank 133 (Table B.7). Therefore, the ANN-Hydro model can be
used in conjunction with IEDB-consensus to improve the efficiency of prediction of CTL
epitopes.
3.3.5 Prediction Validation by in Vivo Discovery of HIV-1 Gag Epitopes
To comprehensively evaluate the predictive capacity of our approach for CTL epitope
discovery and to correlate immunodominance, we interrogated 3 HIV-1 Gag variant pro-
teins: Consensus B (ConsB), 96ZM651.8 (ZM96), and 97/CN54 (CN54) (Fig. 3.4). With
no prior knowledge of Gag-specific CTL epitopes, our model was used to generate a list of
ranked H-2Db restricted peptides, of which the top 20 predictions for each interrogated Gag
sequence are shown (Table B.8). To validate our predicted epitopes in vivo, B6 mice were
immunized independently against each of the three different Gag variants and the peptide
specificity of effector CD8+ T cell responses analyzed using overlapping peptide pools
(Table B.1). Deconvolution and truncation experiments allowed us to define a unique dom-
inant H-2Db-restricted epitope within each Gag protein (SI9 for ConsB, QL11 for CN54,
RT9 for ZM96), as well as shared subdominant epitopes: Db-restricted RT9, AI9, YI9 and
Kb-restricted VL8 (Fig. 3.4 F-H) and (Table B.2). Comparison of empirically defined
epitopes to predictions made using ANN-Hydro revealed that H-2Db restricted 9mer CTL
epitopes for HIV-1 CN54 Gag and ZM96 Gag correlated with ANN-Hydro model epitope
sequences predicted within the top 15 ranked peptides; and for ConsB Gag within the top 11
ranked peptides (Table B.7). In striking contrast, prediction of the identified Gag epitopes
by individual prediction algorithms was more varied, with predictions up to rank number
46, depending on the binding or processing algorithm used. Although the IEDB consensus-
binding and NetMHCpan algorithms predicted the identified Gag epitopes within the top
6 ranked peptides, the performance of these algorithms (unlike the ANN-Hydro model)
was highly variant with the antigen selected (variance ranges from 66.72 to 220.27; (Ta-
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ble B.7)). In sum, the ANN-Hydro model predicted 52 out of 53 experimentally validated
H-2Db and HLA-A2 9mer epitopes from 13 different antigens within the top 20 ranked
peptides (Fig. 3.5), corresponding to a 98% success rate in identifying immunogenic epi-
topes. Moreover, this predictive improvement was reflected in lower variability of epitope
identification, a variance of 37.72 using ANN-Hydro as opposed to 66.72 by IEDB alone
(P< 0.05, F-test).
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Figure 3.4: ANN-Hydro model prediction validation by in vivo discovery of HIV-1 Gag epitopes.
Predictions for H-2Db epitopes were made for 3 HIV-1 Gag proteins using the ANN-Hydro model
and then a blinded epitope discovery study was performed in vivo. The top 20 predicted peptides for
each protein using the model is shown in Table B.7. B6 mice were immunized with AdHu5 vaccines
expressing the ConsB, CN54, or ZM96 Gag, and CD8+ T cell responses determined by intracellular
IFN- or IFN- ELISPOT after ex vivo stimulation with peptide pools of 15mer peptides (overlapping
by 11mer) spanning the entire Gag sequence (ConsB or CN54, (Fig. 3.5 A and B)) or with a
complete set of overlapping 20mer peptides spanning ZM96 (Fig. 3.4 C). Positive responses to pools
were deconvoluted by stimulation with individual 15mer peptides from the positive pools (ConsB or
CN54, (Fig. 3.5 D and E)). Minimal epitopes were identified by stimulation with truncated peptides
and are shown (Fig. 3.4 F-H).
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3.3.6 Prediction of Immunodominant Epitopes
The probabilities of immunogenicity assigned by ANN-Hydro were interrogated with
respect to epitope immunodominance using three antigens with a clear vertical epitope hi-
erarchy (identified by ex vivo experimental data) (Oukka et al., 1996; van der Most et al.,
1998) and this study). The epitope hierarchy defined experimentally in LCMV-GP, Flu-
NP, and ZM96 Gag showed robust correlation with the probabilities of immunogenicity
assigned by ANN-Hydro (r> 0.94,P< 0.05; (Fig. 3.5 B-D)). In contrast, predicted MHC-
binding assigned by IEDB-consensus showed no correlation with epitope immunodomi-
nance in LCMV-GP and ZM96-Gag (Fig. 3.5 E and G). Epitope immunodominance in Flu-
NP correlated with both predicted ANN-Hydros probability and predicted MHC-binding
(Fig. 3.5 C and F). As a further correlate, seven of 13 epitopes predicted in lower rank-
ings by ANN-Hydro along with IEDB-consensus were modest immunogens derived from
LCMV-GP, LCMV-NP, ZM96, CN54, and Consensus Gag (Table B.7). Therefore, efficient
pMHC-TCR affinity may contribute towards epitope immunodominance. By using ANN-
Hydro, epitope predictions were consistently less variable, and improved the prediction of
immunodominant CTL epitopes.
3.4 Discussion
At present, there is no consensus on the molecular mechanisms by which CD8+ T cells
discriminate immunogenic antigens within the background of poorly immunogenic self-
peptides. Understanding this discrimination has implications in rational vaccine design
and the identification of antigenic targets of malignant and autoimmune diseases. While
several theories have been proposed to explain the concept of self/non-self discrimination
(Pradeu and Carosella, 2006), the present study is the first attempt to provide a biochemi-
cal explanation for this fundamental phenomenon. We show that relative aa hydrophobicity
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within immunogenic epitopes reveal an antigenic pattern that could be recognized by TCRs.
We leveraged these findings to design an immunogenicity model, which was trained and
validated using experimentally defined epitopes. ANN-Hydro consistently reduced vari-
able standard prediction outputs across multiple antigens, demonstrating an important step
forward in reducing the empirical element of T cell epitope prediction.
40
Figure 3.5: Incorporating ANN-Hydro in the IEDB-consensus binding tool improves epitope pre-
diction. (A) Ranked epitopes are shown by scatter plots for 26 H-2Db CTL epitopes from 8 well-
described antigens: LCMV-GP, LCMV-NP, AdV.E1B, Flu-NP, Flu-NA, and 3 HIV-1 Gag variants
(ConsB, ZM96, CN54); and for 27 HLA-A2 CTL epitopes from 5 tumor antigens: Melan-A, Wt-1,
gp100, TRAG-3, and p53. Prediction algorithms used are: IEDB-Bind: IEDB consensus binding
tool; NetMHC-Bind: NetMHCpan binding tool; SYFPEITHI: SYFPEITHI epitope prediction tool;
IEDB-Prot: IEDB recommended processing prediction; ANN-Prot: IEDB processing predictions
using ANN. Epitopes and their corresponding predicted ranks by prediction algorithms are shown
in Table B.7. (B-D) Epitope immunodominance as a function of probability of immunogenicity for
LCMV-GP, Flu-NP, and Gag-ZM96. (E-G) Epitope immunodominance as a function of predicted
MHC-binding (IEDB-consensus) for LCMV-GP, Flu-NP, and Gag-ZM96. Immunodominance was
determined from percentage-specific lysis of target cells ex vivo (B and E, 9mer versions of SGV11
and CSA10 were used) (van der Most et al., 1998), percentage-survival of peptide-primed mice
upon lethal challenge of virus (C and F) (Oukka et al., 1996), or IFN--spots/million cells upon ex
vivo peptide stimulation post-vaccination with antigen (D and G) (this study).
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The majority of antigens within the immunogenic dataset used in this study are derived
from intracellular pathogens, such as viruses, which have been shown to favor a lower G+C
genomic content, reflected in their aa usage (Calis et al., 2010). Strongly hydrophobic aas
(e.g. L, I, V, F, M) are characterized by low G+C codons while hydrophilic aas are not
(Khrustalev and Barkovsky, 2011). This suggests the possibility that pathogens, in general,
have a higher usage of hydrophobic aas that could be exploited for TCR recognition. A sec-
ond possibility is that antigen presentation inherently favors hydrophobic regions within a
protein. A recent study demonstrated that exposing hydrophobic domains significantly en-
hances the rate of proteasomal degradation and MHC presentation (Huang et al., 2011).
Moreover, immunogenic CTL epitopes are also positionally biased towards the center of
their source antigens (Kim et al., 2013), consistent with the fact that cytosolic proteins with
a central hydrophobic core are the major substrates of proteasomal degradation. Thus, pro-
tein hydrophobicity can enhance both antigen presentation and immunogenicity, perhaps an
evolutionary adaptation of hydrophobicity driven by damage-associated molecular patterns
(Seong and Matzinger, 2004). TCRs are estimated to recognize on average about 5 non-
anchor residues of a presented peptide because of the angle of peptide contact (Hennecke
and Wiley, 2001; Burroughs et al., 2004). For 3 pMHC allomorphs analyzed by hydropho-
bicity in this study, only 4-5 positions on the peptide were significantly different between
immunogenic and non-immunogenic peptides (Fig. 3.2), similar to published pMHC-TCR
structures (Rudolph et al., 2006). This hydrophobicity difference is relative, not absolute.
Certain aa positions in the peptide may be hydrophilic (e.g. P4 in HLA-A2 9mers, (Fig.
3.2 B)). However, even in such inherently hydrophilic residues in the peptide, immunogenic
epitopes are less hydrophilic (more hydrophobic). Covering exposed hydrophobic residues
on the peptide by a TCR may be a thermodynamically favorable process, facilitating the
pMHC-TCR interaction as noted in retrospect, by a recent study (Birnbaum et al., 2014).
TCR-engagement of pMHC complexes may be enhanced by water-exclusion from the im-
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munological synapse or by increased Kon rates of the TCR-pMHC complex by relatively
hydrophobic aas.
In the absence of a good understanding of the biochemical composition of peptide lig-
ands that result in T cell activation, current strategies for epitope discovery either rely on the
unbiased synthesis of a large number of overlapping peptides, or use MHC-binding/antigen
processing algorithms to select candidate peptides. While the former is an expensive and
laborious process, the latter results in a large number of false positive peptides that are
not immunogenic. Advances in the development of combinatorial technologies have al-
lowed the rapid identification and characterization of antigen-specific T cells (Newell and
Davis, 2014). However, even such novel technologies rely on binding predictions to cre-
ate candidate peptides lists that require extensive empirical validation. For instance, 77
candidate good-binders for HLA-A2 from the rotavirus proteome were chosen for recom-
binant pMHC tetramer production based on their MHC-binding capability, but only 6 (four
being 9mer epitopes) were confirmed to be immunogenic epitopes (Newell et al., 2013).
Therefore, T cell antigen discovery studies need strategies that improve the efficiency of
epitope prediction. ANN-Hydro assigned high probabilities of immunogenicity to 80% of
the HLA-A2 9mer epitopes described in the three proteome wide studies. Of note, three
of the four rotavirus 9mer epitopes from the data set scored a probability of immunogenic-
ity greater than 0.8 (Table B.6). In the HIV-1 Gag study, over 364 overlapping peptides
were tested in vivo from the Gag variants (length: 500aa) for epitope discovery. Using
the ANN-Hydro model combined with SB scores narrows the validation discovery process
down to 11-15 peptides per Gag protein to be tested. Similarly, applying ANN-Hydro also
improved predictions of immunogenic H-2Db and HLA-A2 epitopes from 10 independent
antigens compared to individual prediction algorithms. Thus, models such as ANN-Hydro
adds an extra dimension (immunogenicity) to MHC-binding for CTL epitope prediction
and could be used to significantly reduce the variability associated with standard predic-
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tion algorithms, and the time and cost of experimental validation (Fig. 3.5), (Table B.7).
With the advent of tumor exome sequencing in immune therapy settings, we anticipate that
immunogenicity models such as ANN-Hydro will be critical in identifying immunogenic
neo-antigens for tumor immune therapies (Snyder et al., 2014; Yadav et al., 2014).
The ANN-Hydro model differs from existing MHC-binding/antigen-processing predic-
tion algorithms in two respects: First, the ANN-Hydro was trained on a relative hydropho-
bicity scale, which facilitates the model to discover complex numeric relationships between
different aa residues. Second, the dataset used for training was immunogenic epitopes and
non-immunogenic self-peptides, which do not differ in binding motifs but only in immuno-
genicity. While some high-binding epitopes (e.g. SI9 from ConsB) are readily predicted by
all algorithms, other epitopes (e.g. the immunodominant dominant RT9 from ZM96, LL9
from LCMV-GP) are predicted at variable rankings by different algorithms (Table B.7).
In comparison, ANN-Hydro rescued these epitopes by virtue of their probability of im-
munogenicity. Although ANN-Hydro marks a step forward in efficiently predicting 9mer
epitopes, it is currently limited in terms of predicting longer or shorter epitopes, exemplified
by the 11mer epitope (QL11) deduced by epitope mapping from the CN54 Gag protein. To
improve longer or shorter epitope predictions, larger representative datasets are required
for training. Nonetheless, the model predicted a 9mer version of this epitope ranked at
35 and 44, which is consistent with presentation of nested length peptides (Riemer et al.,
2010). A second limitation of the current model is its applicability to predict epitopes for
other HLA class I alleles. In theory, the ANN-Hydro model could be applied to predict
CTL epitopes for any MHC class I allele, but large representative datasets are required
for training the model for representative MHC allomorphs. We anticipate that advances
in mass spectrometry-based MHC peptide discovery will result in more extensive training
databases for predicting longer and shorter epitopes from a broader selection of HLA class
I molecules (Riemer et al., 2010; Tan et al., 2011).
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While immunogenicity models have been developed by others for prediction of CTL
epitopes (Calis et al., 2013; Harndahl et al., 2012), they considered only the impact of
pMHC stability and positional significance along the peptide for immunogenicity. In con-
trast, a crucial feature of our approach is the use of ligand-eluted non-immunogenic self-
peptides as the comparator set. Because binding and antigen processing are required for
all epitopes, we built upon existing algorithms for immunogenic pMHC predictions. “Lay-
ering” the immunogenicity model on top of existing prediction algorithms enabled us to
predict epitopes with increased effectiveness than standalone predictions. Importantly, the
empirical evaluation of our immunogenicity model and epitope prediction approach with-
out a priori knowledge of the immunodominant HIV-1 Gag epitopes in vivo gives strong
support for these results. In summary, integrating aa hydrophobicity into pMHC prediction
algorithms should significantly enhance the success of epitope discovery. The biological
mechanism underlying TCR preferences for non-polar hydrophobic residues remains to be
evaluated.
3.5 Materials and Methods
For full details of methods and construction of data sets see SI Appendix.
3.5.1 Construction of Datasets
All MHC-I peptides used in this study and design of the ANN-Hydro prediction model
were retrieved from IEDB (Vita et al., 2010) (www.iedb.org, last accessed: 08/11/2013).
Epitopes with a positive T cell response represent the immunogenic epitope group. The
non-immunogenic self-peptide group represent cell surface ligand eluted MHC-I self-peptides
that have been antigenically processed and MHC-bound. Additional curation and exclusion
criteria resulted in a final dataset with 5,035 8-11mer immunogenic epitopes and 4,853 8-
11mer non-immunogenic peptides (See SI for further details.
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3.5.2 Amino Acid Scales
These were derived from Expasys ProtScale (http://web.expasy.org/protscale/) (Gasteiger
et al., 2005), specifically, Hydrophobicity scale (Kyte and Doolittle) (Kyte and Doolittle,
1982), Polarity (Grantham) (Grantham, 1974), and Bulkiness (Zimmerman) (Zimmerman
et al., 1968). The scales are relative, e.g., negative to positive values in the hydrophobicity
scale correspond to a relative hydrophobicity increase between aas (Table B.3).
3.5.3 Position-based Hydrophobicity Analysis
We transformed our datasets of immunogenic and non-immunogenic peptides into nu-
meric arrays using the R statistical software (RDevelopment, 2012). Separate numeric
arrays were generated for immunogenic and non-immunogenic 8, 9 and 10mers. Mean hy-
drophobicity of immunogenic and non-immunogenic peptides at each position was calcu-
lated and were compared residue-by-residue through Wilcoxon rank-sum tests to quantify
statistical significance.
3.5.4 Hydrophobicity-based ANN Prediction Model (ANN-Hydro)
The R neuralnet package was used to design and train the two ANN-Hydro models
on H-2Db and HLA-A2 restricted 9mer peptides known to be immunogenic (n = 204 and
n = 374, respectively) or non-immunogenic (n = 232 and n = 201, respectively). Each
peptide sequence in the respective H-2Db and HLA-A2 datasets were transformed into a
corresponding numeric sequence based on aa hydrophobicity using R statistical software.
A three-layer fully connected feed-forward ANN was comprised by nine input neurons,
one hidden layer with three neurons, and one output variable (Fig. B.3).
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3.5.5 Application of ANN-Hydro
For each H-2Db and HLA-A2 restricted epitope prediction, we used IEDB-consensus
to generate a list of epitope predictions. Each peptide was assigned a normalized binding
score (SB) and a subset of these predicted peptides was then selected by defining a SB -
threshold of 0.1 for antigen length> 100 aas and a SB -threshold of 0.2 for antigen length≤
100 aas. Independently, probabilities of immunogenicity were obtained by applying ANN-
Hydro to this subset of binding predictions. Normalized scores (SI) were then assigned
based on the probabilities of immunogenicity (Fig. B.3). The list of predicted peptides
was ranked based on a total score, S = SB SI, ranging from lowest score to the highest
score. The lower the total score of a predicted peptide, the higher its probability of being
an immunogenic epitope. See SI for details.
3.5.6 Vaccines
Recombinant Adenovirus type 5 (rAdHu5) vectors encoding codon optimized HIV-1
Gag from Cons B, strain 96ZM651.8 (ZM96) and strain 97CN54 (CN54) (Bachy et al.,
2013) are described in SI Materials and Methods.
3.5.7 Immunization of Mice
C57BL/6 mice were immunized with 109 virus particles. All animal studies were con-
ducted in accordance with UK Home Office regulations and Kings College London ethics
committee.
3.5.8 Peptides
15mer peptides spanning HIV-1 CN54 Gag and a 20mer set of peptides spanning HIV-1
ZM96 were provided by the UK Centre for AIDS Reagents. 15mer peptides spanning HIV-
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1 Cons B Gag were provided by the NIH AIDS Reagent Reference Program. Truncated
HIV-1 Gag peptides were purchased from Proimmune.
3.5.9 T Cell Epitope Mapping
Spleen cells were re-stimulated either with media alone or with peptides, either in pools
or individually (each at 1M final concentration) and IFN- production was detected by in-
tracellular cytokine staining or by ELISPOT assay as previously described (Bachy et al.,
2013). Cons B and CN54 Gag epitopes were deconvoluted to individual 15mers from pep-
tide pools, and truncated versions of the 15mer peptides were synthesized and tested. For
ZM96 Gag, 49 individual 20mer peptides were tested. Reactive peptide sequences were
confirmed against the corresponding 15mer peptide to the reactive sequence and 9mer pep-
tides were synthesized and tested.
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Chapter 4
MODELING THE EFFECT OF EARLY DETECTION OF EBOLA VIRUS DISEASE
This chapter is an extension of the work published in the paper:
Modelling the effect of early detection of Ebola
Diego Chowell, Carlos Castillo-Chavez, Sri Krishna, Xiangguo Qiu, Karen S. Anderson
The Lancet Infectious Diseases 15.2 (2015): 148-149
Abstract
The most recent Ebola outbreak in West Africa highlighted critical weaknesses in the med-
ical infrastructure of the affected countries, including effective diagnostics tools, sufficient
isolation wards, and enough medical personnel. Here, we develop and analyze a mathemat-
ical model to assess the impact of early diagnosis of pre-symptomatic individuals on the
transmission dynamics of Ebola virus disease in West Africa. Our findings highlight the
importance of implementing integrated control measures of early diagnosis and isolation.
The mathematical analysis shows a threshold where early diagnosis of pre-symptomatic
individuals, combined with a sufficient level of effective isolation, can lead to an epidemic
control of Ebola virus disease.
4.1 Introduction
The Ebola viral strains are re-emerging zoonotic pathogens and members of the Filoviri-
dae family consisting of five distinct species: Bundibugyo, Cotes d’Ivoire, Reston, Sudan,
and Zaire with a high case-fatality rate in humans (Kugelman et al., 2015). Filoviruses
are long filamentous enveloped, non-segmented, single-stranded viruses, consisting of a
negative-sense RNA genome (Beeching et al., 2014). Each Ebola species genome encodes
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seven linearly arranged genes: nucleoprotein (NP), polymerase cofactor (VP35), matrix
protein (VP40), glycoprotein (GP), replication-transcription protein (VP30), matrix pro-
tein (VP24), and RNA-dependent RNA prolymerase (L) (Beeching et al., 2014). While
there are no proven effective vaccines or effective antiviral drugs for Ebola, containing an
outbreak relies on contact tracing and on early detection of infected individuals for isola-
tion and care in treatment centers (Beeching et al., 2014). The most recent Ebola outbreak
in West Africa, which began in December 2013, due to the Zaire strain, demonstrated sev-
eral weaknesses in the medical infrastructure of the affected countries, including the urgent
need of effective diagnostics, which have a fundamental role in both disease control and
case management.
The Ebola virus is transmitted as a result of direct contact with bodily fluids contain-
ing the virus (Fauci, 2014). The virus enters via small skin lesions and mucus membranes
where it is able to infect macrophages and other phagocytic innate immune cells lead-
ing to the production of a large number of viral particles (Beeching et al., 2014). The
macrophages, monocytes, and dendritic cells infected in the early stage of the disease
serve to spread the virus throughout the organs, particularly in the spleen, liver, and lymph
nodes (Beeching et al., 2014). Consequently, critically ill patients display intensive viremia
(McElroy et al., 2014). Recognizing signs of Ebola viral disease is challenging because it
causes common non-specific symptoms such as fever, weakness, diarrhea, and vomiting,
and the incubation period typically lasts 5 to 7 days (Fauci, 2014). Therefore, function-
ing laboratories and effective point-of-care diagnostic tests are critically needed in order to
minimize transmission, allow better allocation of scarce healthcare resources, and increase
the likelihood of success of antiviral treatments as they are developed (Fink, 2015).
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There is an ongoing effort in place to improve Ebola diagnostics, primarily to detect the
disease early. In our current state, the cost and difficulty of testing limit diagnostic facili-
ties to small mobile laboratories or centralized facilities with turnaround times measured in
days rather than in a few hours, meaning that diagnosis is largely used to confirm disease.
Ebola diagnosis can be achieved in two different ways: measuring the host-specific immune
response to infection (e.g. IgM and IgG antibodies) and detection of viral particles (e.g.
ReEBOV Antigen Rapid Test Kit for VP40), or particle components in infected individuals
(e.g. RT-PCR or PCR). The most general assay used for IgM and IgG antibody detection
are direct ELISA assays. Considering the physiological kinetics of the humoral immune
system as well as impaired antigen-presenting cell function as a result of viral hemorrhagic
fever, antibody titers are low in the early stages and often undetectable in severe patients
prior to death (Ippolito et al., 2012). This leaves polymerase chain reaction (PCR) for anti-
gen detection as a viable option for early diagnostic assays. PCR is a chemical reaction that
amplifies pieces of a virus’s genes floating in the blood by more than a millionfold, which
makes detection of pre-symptomatic individuals likely identifiable. Indeed, a research ar-
ticle published in 2000, illustrates the power of this technology to detect Ebola virus in
humans in the pre-symptomatic stage (Leroy et al., 2000). In this study, 24 asymptomatic
individuals who had been exposed to symptomatic Ebola patients were tested using PCR.
Eleven of the exposed patients eventually developed the infection. Seven of the 11 tested
positive for the PCR assay. And none of the other 13 did.
In this chapter, we extend the work presented in (Chowell et al., 2015). Here, we have
developed and analyzed a mathematical model to evaluate the impact of early diagnosis of
pre-symptomatic individuals on the transmission dynamics of Ebola virus disease in West
Africa, under the assumption that the disease is maintained possibly at very low levels due
to the deficiencies in health systems and our incomplete understanding of Ebola infection
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as illustrated by the case of Pauline Cafferkey. Therefore, eliminating Ebola may require a
more sustained and long-term control effort.
4.2 Model Formulation
The total population is assumed to be classified into six mutually exclusive subgroups:
susceptible S(t), non-detectable latent E1(t), detectable latent E2(t), infectious I(t), iso-
lated J(t), and recovered R(t) individuals. Table 4.1 shows the state variables and their
physical meaning. The transition between all these states is shown in Fig. 4.1. And model
parameters and their description are presented in Table 4.2. Parameter values have been
obtained from previous studies (Chowell and Nishiura, 2014; Fasina et al., 2014).
It is assumed that individuals are recruited (either through birth or migration) into the
susceptible class at a rate Λ and die naturally with rate µ . Susceptible individuals get
infected due to successful contacts with infectious or not perfectly isolated infected indi-
viduals at rate λ . As a consequence, they become latent undetectable, who develop their
state of infection to become latent detectable at rate κ1. We assume that the latent detectable
class represent individuals whose viral load is above the detection limit of the PCR-based
diagnostic test (Leroy et al., 2000; Qiu et al., 2014) . Latent detectable individuals either are
diagnosed and get isolated with probability fT or develop symptoms to become infectious,
who sequentially either get isolated at rate α , or are removed from the system by recovery
or Ebola-induced death at rate γ . It is assumed here that Ebola-induced deaths occur for the
infectious individuals with probability q1. Similarly, isolated individuals leave their class
at rate γr, by either dying due to Ebola with probability q2, or they recover and become
immune. It is assumed that isolation is partially effective so that successful contacts with
susceptible individuals may lead to infection with probability r; this parameter is a measure
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of isolation effectiveness of infectious individuals. Thus, the force of infection is given by
λ (t) =
β [I(t)+(1− r)`J(t)]
N(t)− rJ(t) . (4.1)
Figure 4.1: Compartmental Model Showing the Transition Between Model States.
Table 4.1: Definition of model states.
Variable Description
S(t) Number of susceptible individuals at time t
E1(t) Number of latent undetectable individuals at time t
E2(t) Number of latent detectable individuals at time t
I(t) Number of infectious individuals at time t
J(t) Number of isolated individuals at time t
R(t) Number of recovered individuals at time t
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Table 4.2: Definition of model parameters.
Parameter Value Unit Description
Λ 17182 populationday Recruitment rate
β 0.3335 day−1 Mean transmission rate
µ 4.98×10−5 day−1 Natural death rate
κ1 1/4 day−1 Transition rate from undetectable to detectable latent state
κ2 1/3 day−1 Exit rate of latent detectable individuals by either
becoming infectious or moving to isolation state
γ 1/6 day−1 Removal rate of infectious individuals by either recovery
or Ebola-induced death
γr 1/7 day−1 Removal rate of isolated individuals by either recovery
or Ebola-induced death
α 1/5 day−1 Rate at which infectious individuals get isolated
fT 0.25 ∈ [0,1] – Fraction of latent detectable individuals who are diagnosed
and get isolated
q1 0.7 – Probability that an infectious individual dies due to Ebola
q2 0.63 – Probability that an isolated individual dies due to Ebola
r 0.35 ∈ [0,1] – Effectiveness of isolation
` 0.5 ∈ [0,1] – Relative transmissibility of isolated individuals
with respect to infectious individuals
The assumptions mentioned above lead to the following model of equations
dS
dt
= Λ−λS−µS,
dE1
dt
= λS− (κ1+µ)E1,
dE2
dt
= κ1E1− (κ2+µ)E2,
dI
dt
= (1− fT )κ2E2− (α+ γ+µ)I, (4.2)
dJ
dt
= fTκ2E2+αI− (γr +µ)J,
dR
dt
= (1−q1)γI+(1−q2)γrJ−µR
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where
N(t) = S(t)+E1(t)+E2(t)+ I(t)+ J(t)+R(t)
is the total population size at time t. On adding all equations of system (4.2) together, we
get
dN
dt
= Λ−µN−q1γI−q2γrJ. (4.3)
4.3 Model Analysis
4.3.1 Basic properties
Since model (4.2) imitates the dynamics of human populations, all variables and pa-
rameters should be non-negative. Thus, following the approach shown in appendix A of
(Thieme, 2003), we show the following result.
Theorem 1. The variables of model (4.2) are non-negative for all time.
Lemma 1. The closed set
Ω=
{
(S,E1,E2, I,J,R) ∈ R6+ :
Λ
µ+q1γ+q2γr
≤ S+E1+E2+ I+ J+R≤ Λµ
}
is positively invariant for model (4.2) and is absorbing.
Proof: Equation (4.3) implies that
dN
dt
≤ Λ−µN, (4.4)
dN
dt
≥ Λ− (µ+q1γ+q2γr)N. (4.5)
It follows from (4.4) that
N(t)≤ Λ
µ
+
(
N(0)− Λ
µ
)
e−µt (4.6)
and from (4.5) that
N(t)≥ Λ
µ+q1γ+q2γr
+
(
N(0)− Λ
µ+q1γ+q2γr
)
e−(µ+q1γ+q2γr)t . (4.7)
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If we assume N(0) > Λ/µ , then dN/dt < 0 and therefore (based on inequality (4.6)),
N(t) decreases steadily until reaching Λ/µ when t tends to ∞. Similarly, if we assume
N(0) < Λ/(µ + q1γ + q2γr), then dN/dt > 0 and therefore (based on inequality (4.7)),
N(t) increases steadily until reaching a maximum at Λ/(µ + q1γ + q2γr) when t tends to
∞. It remains to check the case if N(0) lies in the phase between Λ/(µ + q1γ + q2γr) and
Λ/µ . To this end, both inequalities (4.6) and (4.7) are combined together to get
Λ
µ+q1γ+q2γr
+
(
N(0)− Λ
µ+q1γ+q2γr
)
e−(µ+q1γ+q2γr)t ≤N(t)≤ Λ
µ
+
(
N(0)− Λ
µ
)
e−µt .
On taking the limit when t tends to ∞, we find that N(t) remains within the same phase.
Thus, the set Ω is positively invariant and absorbing.
4.3.2 Equilibrium Analysis
Ebola-free equilibrium and the control reproduction numberRc
It is easy to check that model (4.2) has the Ebola-free equilibrium
E0 =
(
Λ
µ
,0,0,0,0,0
)′
(4.8)
where the prime “ ′ ” means vector transpose.
The basic reproduction number, R0, is a measure of the average number of secondary
cases produced by a typical infectious individual during the entire course of infection in
a completely susceptible population and in the absence of control interventions (Brauer
et al., 2001; Anderson et al., 1992). On the other hand, the control reproduction number,
Rc, quantifies the potential for infectious disease transmission in the context of a partially
susceptible population due to the implementation of control interventions. When Rc > 1,
the infection may spread in the population, and the rate of spread is higher with increasingly
high values of Rc. If Rc < 1, infection cannot be sustained and is unable to generate an
epidemic. For our model,Rc is computed using the next generation matrix approach shown
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in (Van den Driessche and Watmough, 2002). Accordingly, we compute the matrices F (for
the new infection terms) and V (for the transition terms) as
F =

0 0 β (1− r)`β
0 0 0 0
0 0 0 0
0 0 0 0

, V =

κ1+µ 0 0 0
−κ1 κ2+µ 0 0
0 −(1− fT )κ2 α+ γ+µ 0
0 − fTκ2 −α γr +µ

.
Thus, the control reproduction number is given by
Rc = ρ(FV−1) =
κ1κ2β [(1− fT )(µ+ γr)+(1− r)`(α+ fT (γ+µ))]
(κ1+µ)(κ2+µ)(α+ γ+µ)(γr +µ)
=
κ1κ2β
(κ1+µ)(κ2+µ)(α+ γ+µ)
[
1− fT +(1− r)`
(
α
γr +µ
+ fT
γ+µ
γr +µ
)]
= R0
[
1− α
(α+ γ+µ)
][
1− fT +(1− r)`
(
α
γr +µ
+ fT
γ+µ
γr +µ
)]
(4.9)
where ρ is the spectral radius (dominant eigenvalue in magnitude) of the matrix FV−1 and
R0 =
κ1κ2β
(κ1+µ)(κ2+µ)(γ+µ)
(4.10)
is the basic reproduction number for the model.
The local stability of the Ebola-free equilibrium, E0, for values ofRc < 1 is established
based on a direct use of Theorem 2 in (Van den Driessche and Watmough, 2002). We
summarize our result in the following lemma.
Lemma 2. The Ebola-free equilibrium E0 of model (4.2) is locally asymptotically stable if
and only ifRc < 1.
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Ebola-endemic equilibrium
On putting the derivatives in the left hand side of (4.2) equal zero and solving the resulting
algebraic system with respect to the variables S¯, E¯1, E¯2, I¯, J¯, and R¯, we obtain
S¯ =
Λ
λ¯ +µ
,
E¯1 =
Λ
λ¯ +µ
· λ¯
κ1+µ
,
E¯2 =
κ1
κ2+µ
· Λ
λ¯ +µ
· λ¯
κ1+µ
,
I¯ =
(1− fT )κ2
α+ γ+µ
· κ1
κ2+µ
· Λ
λ¯ +µ
· λ¯
κ1+µ
, (4.11)
J¯ =
κ1
κ2+µ
· Λ
λ¯ +µ
· λ¯
κ1+µ
· κ2
γr +µ
[
fT +(1− fT ) αα+ γ+µ
]
,
R¯ =
1
µ
[(1−q1)γI+(1−q2)γrJ]
where
λ¯ =
β (I+(1− r)`J¯)
N¯− rJ¯ (4.12)
is the equilibrium force of infection. On substituting from (4.11) into (4.12) and simplifying
(with the assumption that λ 6= 0), we get
λ¯ =
µ(Rc−1)
1−Term (4.13)
where
Term =
κ1κ2[q1(1− fT )γ(γr +µ)+(rµ+q2γr)( fT (γ+µ)+α)]
(κ1+µ)(κ2+µ)(α+ γ+µ)(γr +µ)
.
Hence, the Ebola-endemic equilibrium is unique and we show the following lemma.
Lemma 3. Model (4.2) has a unique endemic equilibrium that exists if and only ifRc > 1.
4.3.3 Normalized Sensitivity Analysis onRc
In considering the dynamics of the Ebola system (4.2), we conduct normalized sensitiv-
ity analysis on Rc to determine the impact of parameter perturbations on the transmission
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dynamics of the system. By computing the normalized sensitivity indices, we consider the
percent change in the output with respect to a percent change in the parameter input. Those
parameters with the largest magnitude of change impact the compartment model the most;
the sign indicates whether the change produces an increase or a decrease onRc.
The normalized sensitivity indices forRc are calculated by taking the partial derivative
of Rc with respect to each parameter and multiply the derivative with the ratio of the pa-
rameter toRc. This value represents the percent change inRc with respect to a 1% change
in the parameter value (Caswell, 2001).
Table 4.3: Percent change in Rc with respect to a 1% change in the parameter value, for
a low and a high isolation effectiveness r, and a low and a high value of fT , while keeping
the other parameter values as presented in Table 4.2.
We use the parameters values from (Table 4.2) to study the sensitivity of Rc to each
parameter. We compute normalized sensitivity analysis on all parameters, but we just con-
sider the impact of parameters that are the most sensitive: β ,r, `,γr,γ,α , and fT . The other
parameters (µ,κ1, and κ2) have a very low impact, namely less than 0.001%. The numerical
simulations to the sensitivity of Rc with respect to each of the most sensitive parameters
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are given in (Table 4.3), for two different levels of isolation effectiveness (r = 0.35 and
r = 0.95) and two values of fT ( fT = 0.25 and fT = 0.75), which is the fraction of pre-
symptomatic individuals diagnosed and isolated. The other parameter values are kept as
shown in Table 4.2.
In the case of high isolation effectiveness (r = 0.95), simulations show that both the
removal rate, γr, of isolated individuals and the relative transmissibility parameter ` of iso-
lated individuals with respect to infectious individuals are the least sensitive parameters
(with 0.053% change of Rc), while the parameter of isolation effectiveness, r, is the most
sensitive one, where a 1% increase in r causes a 1.014% reduction in the value ofRc. Also,
the rate at which infectious individuals get isolated, α , and the fraction of pre-symptomatic
individuals detected and isolated, fT , impact negatively on the level ofRc, where a 1% per-
cent increase in the value of fT causes approximately a 0.31% decline in the value of the
reproduction number Rc. Thus, as pre-symptomatic individuals are diagnosed and as iso-
lation is highly effective, the number of available infectious individuals who are capable of
transmitting Ebola decreases and therefore, the reproduction number decreases. Also, the
removal (by recovery or Ebola-induced death) rate γ of infectious individuals affects neg-
atively on Rc. Hence, for the case of highly effective isolation, the parameters concerning
early diagnosis and isolation have a significant impact on the reproduction number.
This percent impact of the parameters on Rc remains so as long as isolation is highly
effective. However, if the effectiveness of isolation is low, in the sense that all parameter
values are kept the same except the value of the parameter r, which is reduced to 0.35, then
we get the results presented in Table 4.3. In this case, both the relative transmissibility ` and
the removal rate of isolated individuals, γr, are the second most sensitive parameters, after
β which is the most impactful one. Also, ` became more sensitive than r. The implication is
that, when isolation is less effective, there exists the possibility for isolated people to make
successful contacts with susceptible individuals and therefore the possibility of causing
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new infections increases. This causes an increase in the reproduction number. Also, it is
noted that the effect of fT and α is reduced, which means that diagnosing and isolating
infected individuals becomes a weak strategy if the effectiveness of isolation is low.
On repeating the previous analyses, but this time for a higher value of fT ( fT = 0.75),
we obtain the results shown in Table 4.3. In comparison to the scenario when fT = 0.25,
the simulations show that increasing the fraction of pre-symptomatic individuals who are
diagnosed and isolated, fT , increases the percent impact of the parameters r, `,γr, and fT ,
and decreases the percent impact of the parameters γ and α , on the value of the control
reproduction numberRc.
Figure 4.2: Impact of Early Detection of Pre-Symptomatic Individuals on the Value ofRc.
4.3.4 Impact of Early Detection and Isolation on the Value ofRc
To study the impact of early detection of pre-symptomatic individuals and isolation on
the reproduction number, we first depict Rc as a function of fT , for different levels of iso-
lation effectiveness r. Fig. 4.2 shows that the control reproduction number declines as the
proportion, fT , of pre-symptomatic individuals, who get diagnosed and isolated, increases.
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Simulations are done using parameter values from (Table 4.2), but for three different val-
ues of r. It further shows that the curve corresponding to a low and an intermidate value of
isolation effectivenes r (e.g. r = 0.35 for the solid curve and r = 0.65 for the dashed curve)
hitsRc = 1 at some critical value of fT (say f ?T ), while for the high value of r (r = 0.95), it
never hits the critical threshold Rc = 1, as the curve is totally below the critical threshold.
This indicates that for a high effectiveness of isolation, the control reproduction number is
less than one and therefore the infection dies out. Analytically, the exact form of f ?T is
f ?T =
[
1+(1− r)` α
γr +µ
− 1
R0
(
1+
α
γ+µ
)]
/
[
1− (1− r)`(γ+µ)
γr +µ
]
. (4.14)
The critical proportion f ?T represents the minimum proportion of pre-symptomatic individ-
uals who are detected and get isolated to ensure an effective control of Ebola. This critical
value remains feasible as long as the following inequality holds
(1− r)` < γr +µ
(γ+µ)R0
. (4.15)
If we keep all parameters fixed except r, then condition (4.15) could be rewritten in a more
convenient form
r > 1− γr +µ
`(γ+µ)R0
. (4.16)
This gives the minimum level of effectiveness of isolation required to obtain an isolation
and early diagnosis-based control strategy for Ebola tranmission.
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Figure 4.3: Impact of Isolating Infectious Individuals on the Value ofRc.
Now, we could also ask a similar question on the role of isolating infectious individuals
to contain Ebola transmission. Fig. 4.3 shows the impact of changing the rate at which
infectious individuals get isolated, α , onRc, for the same three different levels of isolation
effectivenes, as used above. The analysis shows that it is possible to control the epidemic
if and only if α > α?, where
α? =
[(1− fT )(γr +µ)(γ+µ)+(1− r)` fT (γ+µ)2]R0− (γr +µ)(γ+µ)
(γr +µ)− `(1− r)R0(γ+µ) (4.17)
and with the implementation of condition (4.15).
4.4 Discussion
The Ebola epidemic has shown us major weaknesses not only in health systems in
West Africa, but also in our global capacity to respond early to an outbreak with effective
diagnositc capacities. After multiple outbreaks of infectious diseases, from severe acute
respiratory syndrome (SARS) to Middle East respiratory syndrome coronavirus (MERS-
CoV), we still do not have effective diagnostic tools to rapidly respond to a number of
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potential epidemics. The main reason why we lack of such diagnostic preparedness against
infectious diseases is because of the lack of a financed global strategy that can be imple-
mented ahead, rather than during an epidemic. This strategy must primarily focus on two
critical aspects: First, a continuous intereaction between the field to detect small outbreaks
and collect samples, and reference laboratories with advanced sequencing tools to identify
the pathogen. Second, the need of assay development for early diagnosis, their regulatory
approval, and a plan of implementation in anticipation of an outbreak.
Here, motivated by some studies showing that PCR assay can detect Ebola virus in both
humans and non-human primates during the pre-symptomatic stage (Leroy et al., 2000;
Qiu et al., 2014), we have developed and analyzed a mathematical model calibrated to
the transmission dynamics of Ebola virus disease in West Africa to evaluate the impact of
early diagnosis of pre-symptomatic infections. In the absence of effective treatments and
vaccines, our results show the importance of implementing integrated control measures of
early diagnosis and isolation. Importantly, our analysis identifies a threshold where early
diagnosis of pre-symptomatic individuals, combined with a sufficient level of effective iso-
lation, can lead to an epidemic control of Ebola virus disease. Furthermore, the need to
incorporate vital dynamics is justified by our still limited understanding of Ebola infection
including whether or not Ebola virus may persist among recovered individuals. The use of
Rc in this context reflect our view that control measures should be sustainable and not just
in response to an outbreak.
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APPENDIX A
MODELING THE SUBCLONAL EVOLUTION OF CANCER CELL POPULATIONS
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Table A.1: Statistics of the number of dominant clones and minor subclones across all combina-
tions of parameter values.
Table A.2: Differential fitness between dominant and minor subclones
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Table A.3: Average time from treatment to disease recurrence. The generation time as-
signed in the simulations is T = 4 days
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APPENDIX B
TCR CONTACT RESIDUE HYDROPHOBICITY IS A HALLMARK OF
IMMUNOGENIC CD8+ T CELL EPITOPES
82
B.1 Construction of Datasets
All MHC class I peptides used in this study for analyses and the design of ANN-Hydro
prediction model were retrieved from IEDB Vita et al. (2010) (www.iedb.org, last accessed:
08/11/2014). The IEDB is the largest curated dataset of MHC-I peptides identified from
different primary research studies from over 334 different source organisms. We set the
“Immune recognition context” as T cell response and selected “MHC class I” as the crite-
ria for data retrieval. In total, there were 28,444 T cell epitopes reported to be immunogenic
by T cell assays, including self and pathogenic epitopes and 6,142 peptides were reported
to be positive by ligand elution analysis (either mass spectrometry or HPLC). To avoid
redundancy and overrepresentation bias, we excluded all duplicate peptides, so that each
peptide is present only once in the dataset. Positive CTL epitopes represent the immuno-
genic epitope group. Ligand eluted MHC-I self-peptides are generally eluted from cell
surface and therefore they have been antigenically processed and MHC-bound. A vast
majority of eluted self-peptides are derived from endogenous proteins. To completely sep-
arate immunogenic and non-immunogenic datasets, any immunogenic eluted self-peptide
associated with autoimmunity or cancer was excluded. The remaining peptides were used
as the non-immunogenic peptide dataset for our analyses. Additionally, we removed any
pathogen derived non-self- eluted peptides from the eluted peptide dataset to generate mu-
tually exclusive datasets. These unique peptides were further annotated for antigen name,
peptide starting position, peptide ending position, and MHC restriction, which were re-
quired for inclusion. Peptides with “undetermined class I alleles” were also excluded.
These filtering criteria resulted in a final dataset of 5,035 8-11mer immunogenic epitopes
and 4,853 8-11mer non-immunogenic peptides.
B.2 Amino Acid Frequency Analysis
Overrepresentation of certain amino acids in immunogenic peptides was identified by
calculating probability ratios of amino acids given by P(x I immunogenic)/P(x I non−
immunogenic), where P(x I immunogenic) and P(x I non− immunogenic) correspond to
probability mass functions and x is an amino acid. Individual amino acid probability mass
functions were calculated from their frequency distributions of immunogenic epitopes and
non-immunogenic peptides. Spearman’s rank correlations were quantified between prob-
ability ratios and biochemical properties (hydrophobicity, polarity, or bulkiness) of amino
acids using the described amino acid scales.
B.3 Position-based Hydrophobicity Analysis
We transformed our datasets of immunogenic and non-immunogenic peptides into nu-
meric arrays using the R statistical software RDevelopment (2012). Separate numeric ar-
rays were generated for immunogenic and non-immunogenic 8, 9 and 10mers. Mean hy-
drophobicity of immunogenic and non-immunogenic peptides at each position was calcu-
lated and were compared residue-by-residue through Wilcoxon rank-sum tests to quantify
statistical significance.
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B.4 Rate Analysis of Predicted Peptides
An efficient prediction algorithm identifies consistently all possible CTL epitopes from
a given protein in the fewest number of hits consistently. For each test protein, we cre-
ated a subset with unique CTL epitopes retrieved either from the IEDB database. Each
predicted peptide starting from rank one was queried for an exact match in the dataset of
CTL epitopes. When there was an exact match, a positive hit was recorded. Graphical rep-
resentations comparing the rate of predictions by the IEDB-consensus binding prediction
algorithm and hydrophobicity-based predictions were generated (Fig. 3.3).
B.5 Hydrophobicity-based ANN Prediction Model (ANN-Hydro)
The R neuralnet package was used to design and train the two ANN-Hydro models
on H-2Db and HLA-A2 restricted 9mer peptides known to be immunogenic (n = 204 and
n = 374, respectively) or non-immunogenic (n = 232 and n = 201, respectively). Each
peptide sequence in the respective H-2Db and HLA-A2 datasets were transformed into a
corresponding numeric sequence based on the hydrophobicity value of amino acids. Train-
ing peptides were derived from IEDB and SYFPEITHIs epitope database Vita et al. (2010);
Rammensee et al. (1999). A three-layer fully connected feed-forward ANN was com-
prised by nine input neurons, one hidden layer with three neurons, and one output variable
(Fig.B.3).
Our ANN-Hydro prediction model is given by the following mathematical framework:
y(H) = f
(
w0+
3
∑
i=1
wi · f (w0i+W Ti H)
)
,
where w0 denotes the intercept of the output neuron and w0i the intercept of the ith hidden
neuron. Additionally, wi denotes the synaptic weight corresponding to the synapse starting
at the ith hidden neuron and leading to the output neuron. Wi = (w1i,w2i, · · · ,w9i) is the vec-
tor of all synaptic weights corresponding to the synapse leading to theith hidden neuron, and
H = (h(R1),h(R2), · · · ,h(R9)) the vector of all inputs, which corresponds to the numeric
hydrophobicity representation of a 9mer peptide, where h(Ri) is the hydrophobicity value
of the amino acid Ri. Finally, the output variable y(H) denotes the probability of a peptide
being immunogenic (p-ANN-Hydro). Since the starting values for the weights are drawn
from the standard normal distribution, the outputs were averaged over 60 realizations. The
activation function f (v) was chosen to be the sigmoid function f (v) = 1/(1+ e−v), and
the sum of squared errors was used for the error function. The learning procedure was the
resilient back-propagation with learning rate set to 0.01; a threshold set to 0.01 was defined
for the partial derivatives of the error function
B.6 Application of ANN-Hydro
For each H-2Db and HLA-A2 restricted epitope prediction, we used the MHC-binding
prediction tool IEDB-consensus to generate a list of epitope predictions on which the im-
munogenicity model could be applied. We normalized prediction binding scores (percentile
rank) using the expression SBi = (δi−δmin)/(δmax−δmin) where SBi represents the normal-
ized score of a given peptide; δi, the assigned output score by IEDB-consensus; δmin, the
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minimum score assigned in prediction output by IEDB; and δmax , the maximum score as-
signed in the entire prediction output by IEDB. To remove poor binding peptides from the
list, a subset of predicted peptides was selected by defining a SB-threshold of 0.2 for antigen
length≤ 100 aas and a SB-threshold of 0.1 (10th percentile of predicted binders) for antigen
length > 100 aas. Independently, probabilities of immunogenicity were obtained by apply-
ing the ANN-Hydro model to this subset of binding predictions. Normalized scores (SI)
were then assigned based on these probabilities of immunogenicity. Within the spectrum
of predicted binders, we prioritized epitope re-ranking based on both SB and SI scores with
first priority given to high-immunogenicity high-binders (probability of immunogenicity
≥ 0.4 and SB ≤ 0.05; region I in (Fig.B.3)), followed by modest-immunogenicity high-
binders (probability of immunogenicity < 0.4 and SB ≤ 0.05; region II in (Fig.B.3)), then
high-immunogenicity modest-binders (probability of immunogenicity≥ 0.4 and SB> 0.05;
region III in (Fig.B.3)), and modest-immunogenicity modest-binders (probability of im-
munogenicity < 0.4 and SB > 0.05; region IV in (Fig.B.3)). For the antigens with length
≤ 100 aas, the SB cutoff for the four regions was set to 0.1 and probability of immunogenic-
ity threshold remained at 0.4. Predicted peptides in each section were re-ranked based on a
total score defined as S = SB ·SI . Final ranked list was obtained by sequential appending of
the re-ranked peptides from each region. The list of predicted peptides was ranked based on
this total score ranging from lowest score to the highest score. The lower the total score of
a predicted peptide, the higher its probability of being an immunogenic epitope. Workflow
of the prediction strategy is shown in (Fig.3.3).
B.7 Statistical Analysis of Predicted CTL Epitopes
We used the F-test to quantify statistical significance (P< 0.05) of the variation of pre-
dicted rankings of T cell epitopes across different antigens between ANN-Hydro together
with IEDB-consensus and IEDB-consensus alone
B.8 In vivo discovery of HIV-1 Gag Epitopes
Mice
C57BL/6 mice were obtained from Harlan Laboratories. All mice used were between 6 and
8 weeks of age. All animal study protocols were conducted in accordance with guidelines
approved by the Institutional Animal Care and Use Committee at Kings College London
and in full compliance with UK Home Office regulations under a project license to L.S.K.
Vaccine Immunization
Codon optimized HIV-1 gag plasmid DNA ZM96 from strain 96ZM651.8 (provided by
B Hahn, through the Centre for AIDS Reagents [CFAR] UK) and codon optimized HIV-1
gag Consensus B plasmid DNA (provided by D Garber, Emory University, USA) were used
to construct and propagate replication defective (E1, E3 deleted) recombinant Adenovirus
type 5 (rAdHu5) vectors as described previously for the HIV-1 gag strain 97CN54 Bachy
et al. (2013). Animals were immunized with 109 virus particles (vp) as determined by the
DNA Pico-Green assay (Invitrogen) and administered either i.m. in the quadricep muscle
(rAdHu5 Consensus B gag) or i.d. at the base of the tail (rAdHu5 ZM96 and rAdHu5
CN54).
85
Peptides
15mer peptides with an 11 amino acid overlap spanning the HIV-1 CN54 Gag protein and
a 20mer set of peptides with 10 amino acid overlap spanning HIV-1 ZM96 were provided
by CFAR, a set of 15mers with an 11 amino acid overlap spanning the HIV-1 Consensus
subtype B Gag protein were provided from the NIH AIDS Reagent and Reference Pro-
gram. ‘Optimal’ 9mer or 11mer peptides from HIV-1 CN54 Gag, ZM96 Gag and HIV-1
Consensus B were purchased from Proimmune.
T Cell Epitope Mapping by Intracellular Interferon Gamma Staining
Spleens were harvested 14 days after immunization, homogenized to single-cell suspen-
sions, and RBCs were lysed using ACK lysis buffer (Lonza). Splenocytes were then used
for in vitro re-stimulation, where 106 cells were incubated for 6 h at 37C with anti-CD28
(2µg/ml; BD Pharmingen), either alone (unstimulated control) or with peptides, either in
pools or individually (each at 1µg peptide/ml), derived from Consensus B Gag. Brefeldin A
(10µg/ml, Sigma-Aldrich) was added for the last 5 h of culture. After washing, cells were
stained with anti-CD8 (clone 37.51, BD Biosciences) for 20 min, then fixed and permeabi-
lized with the BD Cytofiix/Cytoperm Kit according to the manufacturers instructions, and
then stained 30 min with anti-IFN-γ (clone XMG1.2, eBiosciences), washed and analyzed
by flow cytometry. Consensus B epitopes were deconvoluted to individual 15mers from
peptide pools, where each peptide is present in two independent pools within the matrix
and reactive peptides confirmed in the second round against the 15mer peptide. Finally,
based on the sequence of the reactive 15mer peptide, truncated versions of the 15mer pep-
tides were synthesized and tested.
T Cell Epitope Mapping by ELISPOT Assay
14 days after immunization, splenocytes prepared (as detailed above) were re-stimulated in
vitro with media alone, or with peptides, either in pools or individually (each at 1µM final
concentration) derived from CN54 or ZM96 Gag on mouse anti-INF-γ antibody coated 96
well plates (U-Cytech) and incubated for 16 h at 37C, 5% CO2. IFN-γ production was
revealed according to the manufacturers instructions and IFN-γ spot forming cells (SFCs)
enumerated using an immunospot image analyser (Bioreader 5000). In the first round,
CN54 Gag epitopes were deconvoluted to individual 15mers from peptide pools, where
each peptide is present in two independent pools within the matrix and reactive peptides
confirmed in the second round against the 15mer peptide. Finally, based on the sequence of
the reactive 15mer peptide, 9mer peptides were synthesized and tested. For ZM96 (due to
the absence of a complete set of overlapping 15mer peptides), 49 individual 20mer peptides
were tested. The reactive peptide sequences were confirmed against the corresponding
15mer peptide to the reactive sequence and then 9mer peptides synthesized and tested.
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Figure B.1: Bias in amino acid usage between immunogenic and non-immunogenic MHC-I
peptides. (A) Comparison of frequency distributions of amino acids between immunogenic and
non-immunogenic datasets. (B) Probability ratio (P(x I immunogenic)/P(x I non− immunogenic))
of each amino acid as a function of its hydrophobicity, analyzed on just 9mer MHC-I peptides. (C)
Probability ratio (P(x I immunogenic)/P(x I non− immunogenic)) of each amino acid as a function
of its hydrophobicity, analyzed on 9mer HLA-I peptides excluding HLA-A2 restricted peptides. (D)
Probability ratio of each amino acid as a function of its hydrophobicity; the plot shows cysteine (C)
as an outlier in the immunogenic dataset.
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Figure B.2: Hydrophobicity comparison at each residue position between immunogenic and
non-immunogenic MHC-I peptides, and immunogenic pathogen-derived and immunogenic
self-epitopes. Each peptide sequence in the dataset was transformed into a numeric sequence based
on amino acid hydrophobicity and the mean hydrophobicity at each position was computed. Un-
less indicated, analyzed peptides were not restricted to any MHC-motifs. (A) All immunogenic
and non-immunogenic MHC-I 10mers; every single residue has P < 2x10−7. (B) Human HLA-
I immunogenic and non-immunogenic 9mers excluding HLA-A2 restricted peptides. (C) Human
HLA-I immunogenic and non-immunogenic 10mers excluding HLA-A2 restricted peptides. (D)
Immunogenic and non-immunogenic MHC-I 9mer self-peptides. (E) MHC-I 9mers peptides dis-
covered using whole organism as immunogen as opposed to peptide-immunization experiments
(non-immunogenic dataset same as (Fig.3.2A)) (F) Human HLA-A2 restricted immunogenic and
non-immunogenic 10mers with arrows indicating anchor residues and stars for P < 0.005. (G)
Human HLA-A2 restricted immunogenic pathogen-derived and immunogenic self 9mer epitopes.
P-values for each figure were obtained using Wilcoxon rank-sum test and are shown in (Table B.4).
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Figure B.3: Workflow for CTL epitope prediction using the ANN-Hydro model and the
MHC-binding prediction tool IEDB-consensus. For training and application of the ANN-Hydro
model for immunogenicity scores, each peptide sequence in the HLA-A2 and H-2Db dataset was
transformed into a corresponding numeric sequence based on the hydrophobicity value of amino
acids. To obtain a list of candidates for MHC-bound peptides from a given antigen, IEDB-consensus
binding algorithm was used and a normalized binding score (SB) was assigned. The trained immuno-
genicity ANN model was applied on the same list of peptides independently to assign immunogenic-
ity scores (SI). After the subset of top binding peptides was selected, peptides from each region rang-
ing from high-binding highly-immunogenic peptides to modest-binding low-immunogenic peptides
(quadrants 1 through 4 in inset) were re-ranked based on total score S = SB · SI . An example of
epitope prediction is shown in the plot for experimentally defined H-2Db restricted CTL epitopes
from LCMV-GP. See Materials and Methods section Application of ANN-Hydro for full details.
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Table B.1: Schematic of ConsB (top) and CN54 (bottom) 15mer peptide pools. Peptides were
combined at 1µM/each peptide such that each peptide occurs in only two pools numbered 7872
7994 for ConsB (top) or 7080.01-7080.121 for CN54 (indicated by 1121, bottom). Yellow highlight
indicates positive response to peptide pool. Green highlight indicates positive response to individual
15mer peptide, and red indicates negative response to individual 15mer peptide.
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Table B.2: Summary of identified epitopes. Responses to the RT9, VL8, AI9, and YI9 epitopes
were observed for all three Gag protein variants, despite minor substitutions in the peptides. Over-
lapping sequences of individual peptides are shown. The QL11 epitope was only immunogenic for
the CN54 Gag protein, but not ConsB or ZM96 Gag proteins, likely due to the A to E substitution
at position 2. The SI9 epitope was only immunogenic in the ConsB Gag protein, as both CN54 and
ZM96 had major deletions and substitutions in this sequence. MHC restriction was confirmed using
MHC class I tetramer staining, and Gag amino acid positions are in reference to the HXB2 strain.
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Table B.3: Amino acid property scales used for analyses Hydrophobicity scale (Kyte-Doolittle)
Kyte and Doolittle (1982), Polarity (Grantham) Grantham (1974), and Bulkiness (Zimmerman)
Zimmerman et al. (1968)
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Table B.4: Hydrophobicity comparison between immunogenic and non-immunogenic MHC
class I peptides. P-values were calculated using Wilcoxon sum-ranked test using different
datasets as described in main text.
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Table B.5: HLA-A2 restricted CTL epitopes for dengue virus 1 polyprotein and cy-
tomegalovirus pp65 used in the rate analysis of predicted epitopes as shown in (Fig.3.3). All
epitopes were retrieved from IEDB Vita et al. (2010).
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Table B.6: Probabilities assigned by the ANN-Hydro A2-model for HLA-A2 restricted 9mer
CTL epitopes. Three recent epitope discovery studies Assarsson et al. (2008); Weiskopf et al.
(2011); Newell et al. (2013) that were based on a proteome-wide screen of various viral antigens
and self-epitopes were chosen for assessment of the predictive capacity of the ‘A2-model’. Neo-
epitopes were obtained from rotavirus Newell et al. (2013) dengue virus Weiskopf et al. (2011)
and influenza A Assarsson et al. (2008) and other positive control epitopes from several antigens
(pathogenic and self) were obtained from Newell et al. Newell et al. (2013). Any epitope that was
present in the training set for ANN-Hydro was removed. A cutoff probability (p-ANN-Hydro) of
0.4 was set for a positive “hit”.
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Table B.7: Ranking comparison of all the predicted epitopes (Prevalidation and in vivo val-
idation) used in this study as shown in (Fig.3.5 A). The predictions used are as follows: ANN-
Hydro - ANN-hydrophobicity prediction model combined with normalized binding scores from
prediction algorithms, IEDB-Bind -IEDB consensus binding tool, NetMHC-Bind - NetMHCpan
binding tool, SYFPEITHI - SYFPEITHI epitope prediction tool, IEDB-Prot-IEDB recommended
processing prediction, ANN-Prot - IEDB processing predictions using ANN. p-ANN-Hydro Proba-
bility of immunogenicity assigned by the corresponding (H-2Db or A2) ANN-Hydro immunogenic-
ity model. All references were obtained from IEDB Vita et al. (2010) and are indicated.
97
98
Table B.8: Ranked list of top 20 predicted peptides for each of the Gag variant using the
ANN-Hydro combined with normalized binding scores from predictions. (SB) - Binding score,
p-ANN-Hydro - probability of immunogenicity obtained by applying ANN-Hydro model to each
peptide, (S) - Total score. This list was ranked based on total score S ranging from lowest score to
the highest score within each section (I through IV) classified based on p-ANN-Hydro and SB (see
section Application of ANN-Hydro).
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